
Handbook of Therapeutic Antibodies
Volume 1: Defining the Right Antibody Composition
Second Edition
Edited by Stefan Dübel and Janice M. Reichert
WILEY Blackwell

Edited by
Stefan Dübel and
Janice M. Reichert

Handbook of Therapeutic Antibodies

Related Titles

Chamow, S.M., Ryll, T., Lowman, H.B., Farson, D. (eds.)

Therapeutic Fc-Fusion Proteins

2014
Print ISBN: 978-3-527-33317-2, also available in digital formats

Knäblein, J. (ed.)

Modern Biopharmaceuticals

Recent Success Stories

2013
Print ISBN: 978-3-527-32283-1, also available in digital formats

Pathak, Y., Benita, S. (eds.)

Antibody-Mediated Drug Delivery Systems

Concepts, Technology, and Applications

2012
Print ISBN: 978-0-470-61281-1, also available in digital formats

Kratz, F., Senter, P., Steinhagen, H. (eds.)

Drug Delivery in Oncology

From Basic Research to Cancer Therapy

2011
Print ISBN: 978-3-527-32823-9, also available in digital formats

Tovey, M.G. (ed.)

Detection and Quantification of Antibodies to Biopharmaceuticals

Practical and Applied Considerations

2011
Print ISBN: 978-0-470-56666-4, also available in digital formats

Edited by Stefan Dübel and Janice M. Reichert

Handbook of Therapeutic Antibodies

Volume I: Defining the Right Antibody Composition

Second Edition

WILEY Blackwell

Edited by Stefan Dübel and Janice M. Reichert

Handbook of Therapeutic Antibodies

Volume II: Clinical Development of Antibodies

Second Edition

WILEY Blackwell

Edited by Stefan Dübel and Janice M. Reichert

Handbook of Therapeutic Antibodies

Volume III: Approved Therapeutic Antibodies

Second Edition

WILEY Blackwell

Edited by Stefan Dübel and Janice M. Reichert

Handbook of Therapeutic Antibodies

Volume IV: Approved Therapeutic Antibodies and in vivo Diagnostics

Second Edition

WILEY Blackwell

Editors

Prof. Dr. Stefan Dübel
Technische Universität Braunschweig
Institute of Biochemistry
Biotechnology and Bioinformatics
Spielmannstr. 7
38106 Braunschweig
Germany

Dr. Janice M. Reichert
Reichert Biotechnology Consulting LLC
Prospect Street 247
Framingham, MA
USA

Cover

Antibodies have become standard therapy in many therapeutic areas including cancer, inflammation, osteoporosis, autoimmune, cardiovascular, ophthalmic and infectious diseases. Early successes in the treatment of leukemia and lymphoma by rituximab and alemtuzumab spawned the development of ofatumumab and obinutuzumab, antibodies that kill tumor cells more potently via diverse mechanisms. The cover is an artist's impression of lymphocytic leukemia cells under therapeutic antibody attack. The image was developed by Joost M. Bakker, www.scicomvisuals.com.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek
The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical, and Medical business with Blackwell Publishing.

Print ISBN: 978-3-527-32937-3
ePDF ISBN: 978-3-527-68245-4
ePub ISBN: 978-3-527-68244-7
Mobi ISBN: 978-3-527-68243-0
oBook ISBN: 978-3-527-68242-3

Cover Design Formgeber, Mannheim, Germany
Typesetting Laserwords Private Limited, Chennai, India
Printing and Binding Markono Print Media, Pte Ltd., Singapore

Printed on acid-free paper

Contents

Volume I: Defining the Right Antibody Composition

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

1 Therapeutic Antibodies – from Past to Future *1*
Stefan Dübel and Janice M. Reichert
1.1 An Exciting Start – and a Long Trek *1*
1.2 The Gold Rush *6*
1.3 Success and Setbacks *7*
1.4 The Gleaming Horizon *10*
References *12*
Further Reading *12*

Part I: Selecting and Shaping the Antibody Molecule *15*

2 Selection Strategies for Monoclonal Antibodies *17*
Gerhard Moldenhauer
2.1 Introduction *17*
2.2 Historical Remarks *18*
2.3 Antibody Structure and Function *19*
2.3.1 Membrane-Bound and Secreted Forms of Antibodies *19*
2.3.2 Monoclonal Antibodies *21*
2.4 Production of Monoclonal Antibodies *21*
2.4.1 Immunization *21*

2.4.2 Myeloma Cell Lines *22*
2.4.3 Cell Fusion *23*
2.4.4 Drug Selection of Hybridomas *25*
2.4.5 Screening Hybridoma Cultures for Specific Antibody *26*
2.4.5.1 Enzyme-Linked Immunosorbent Assay (ELISA) *27*
2.4.5.2 Flow Cytometry *27*
2.4.5.3 Immunohistology and Immunocytology *28*
2.4.5.4 Cytotoxicity Assays *29*
2.4.5.5 Screening for Function *30*
2.4.6 Cloning *30*
2.4.7 Expansion and Freezing of Hybridoma Clones *30*
2.5 Purification and Modification of Monoclonal Antibodies *31*
2.5.1 Mass Culture and Purification of Monoclonal Antibody *31*
2.5.2 Fragmentation of Monoclonal IgG Antibodies *32*
2.5.3 Labeling of Monoclonal Antibodies *32*
2.6 Monoclonal Antibodies for Tumor Therapy *33*
2.6.1 Leukocyte Differentiation Antigens *33*
2.6.2 Epithelial Differentiation Antigens *33*
2.6.3 Mechanisms of Action of Monoclonal Antibodies *34*
2.6.4 Human Monoclonal Antibodies *35*
2.7 Outlook *36*
References *37*

3 Antibody Phage Display *43*
Michael Hust, André Frenzel, Florian Tomszak, Jonas Kügler, and Stefan Dübel
3.1 Introduction *43*
3.2 Phage Display *45*
3.3 Selection and Screening *46*
3.4 Phage Display Vectors *48*
3.5 Phage Display Libraries *57*
3.6 Construction of Phage Display Libraries *58*
Acknowledgments *65*
References *65*

4 Transgenic Animals Derived by DNA Microinjection *77*
Marianne Brüggemann, Michael J. Osborn, Biao Ma, Suzanne Avis, Ignacio Anegon, and Roland Buelow
4.1 Introduction *77*
4.2 Construction of Human Ig Transloci *78*
4.2.1 IgH *78*
4.2.2 Igκ *80*
4.2.3 Igλ *80*
4.3 BAC Integration *81*

4.4 Designer Zinc Finger Endonucleases to Silence Endogenous Ig Loci *82*
4.5 Expression Comparison of Fully Human and Chimeric IgH Loci *83*
4.6 Outlook *85*
References *85*

5 Humanization Strategies *89*
José W. Saldanha
5.1 Introduction *89*
5.2 History of Humanization *89*
5.3 CDR-Grafting *90*
5.4 The Design Cycle *92*
5.4.1 Analysis of the Source (Donor) Sequence *92*
5.4.1.1 Complementarity-Determining Regions (CDRs) *92*
5.4.1.2 Canonical Residues *93*
5.4.1.3 Interface Packing Residues *93*
5.4.1.4 Rare Framework Residues *94*
5.4.1.5 N- or O-Glycosylation Sites *95*
5.4.2 Three-Dimensional Computer Modeling of the Antibody Structure *95*
5.4.3 Choice of Human Framework Sequences *97*
5.4.3.1 Fixed Frameworks or Best-Fit? *100*
5.4.3.2 VL/VH Frameworks from the Same or Different Clone? *100*
5.4.3.3 Human Subgroup Consensus or Expressed Framework? *101*
5.4.3.4 Germline Frameworks *101*
5.4.3.5 Database Search *101*
5.4.4 Identifying Putative Backmutations *102*
5.4.5 Stability *104*
5.5 Other Approaches to Antibody Humanization *104*
5.5.1 Resurfacing/Veneering *104*
5.5.2 SDR-Transfer *105*
5.5.3 Removal of T- and B-Cell Epitopes *106*
5.5.4 Phage Libraries *106*
References *107*

6 Antibody Affinity *115*
André Frenzel, Lorin Roskos, Scott Klakamp, Meina Liang, Rosalin Arends, and Larry Green
6.1 Introduction *115*
6.2 Affinity Maturation *115*
6.2.1 Affinity Maturation *In Vivo* *115*
6.2.2 Affinity Maturation *In Vitro* *117*
6.3 Antibody Affinity: Antigen Binding and Potency *120*
6.4 Binding and Potency *In Vitro* *121*
6.5 Binding and Potency *In Vivo* *123*

6.6 Selection of High-Affinity Antibodies from Hybridoma Cell Lines *126*
6.7 Generation of Antibodies against Soluble Antigens *126*
6.8 Generation of Antibodies against Cell Surface Antigens *127*
6.9 Determination of Antibody Affinity *128*
6.10 Surface Plasmon Resonance *128*
6.11 Other Methods for Determining Antibody Affinity *131*
6.12 Conclusion *134*
References *134*

7 Fc Engineering *141*
Matthias Peipp, Stefanie Derer, Stefan Lohse, Christian Kellner, and Thomas Valerius
7.1 Mechanisms of Action of Monoclonal Antibodies *141*
7.1.1 Introduction *141*
7.1.2 Preclinical Evidence *142*
7.1.3 Clinical Evidence *144*
7.2 Modifying Effector Functions *145*
7.2.1 Antibody Isotype *145*
7.2.1.1 IgG Antibodies *145*
7.2.1.2 IgA Antibodies *149*
7.2.2 Altered Fc Receptor Binding *151*
7.2.2.1 Introduction *151*
7.2.2.2 Protein-Engineered Antibodies *151*
7.2.3 Altered Complement Activation *157*
7.3 Modifying Antibodies' Pharmacokinetics *158*
7.3.1 Introduction *158*
7.3.2 Modifying Binding to FcRn *159*
7.4 Summary and Conclusions *160*
References *160*

8 Glycosylation of Antibody Molecules *171*
Roy Jefferis
8.1 Introduction *171*
8.2 Overview of the IgG Molecule *172*
8.3 Quaternary Structure of IgG-Fc: The Protein Moiety *174*
8.4 The IgG-Fc Oligosaccharide Moiety *176*
8.5 IgG-Fc Protein/Oligosaccharide Interactions *177*
8.6 Protective Mechanisms Activated by Immune Complexes *180*
8.7 Role of IgG Glycoforms in Recognition by Cellular FγRs *180*
8.8 The Influence of Fucose and Bisecting *N*-Acetylglucosamine on IgG-Fc Activities *180*
8.9 The Influence of Galactosylation on IgG-Fc Activities *182*
8.10 Sialylation of IgG-Fc Oligosaccharides *184*
8.11 Chemo-Enzymatic Synthesis of Novel IgG-Fc Glycans *185*

8.12 Restoration of Functionality to Aglycosylated IgG-Fc *186*
8.13 IgG-Fab Glycosylation *187*
8.14 Conclusion *189*
References *189*

9 Bioinformatics Tools for Analysis of Antibodies *201*
Andrew C.R. Martin and James Allen
9.1 Introduction *201*
9.1.1 Brief Review of Antibody Structure *201*
9.1.2 Conventions Used in this Chapter *202*
9.2 Numbering Schemes for Antibodies *202*
9.2.1 The Kabat Numbering Scheme *203*
9.2.1.1 The Chothia Numbering Scheme *204*
9.2.2 The IMGT Numbering Scheme *206*
9.2.3 Honegger and Plückthun (Aho) Numbering Scheme *206*
9.2.4 Enhanced Chothia (Martin) Numbering Scheme *206*
9.2.5 Numbering Scheme Summary *206*
9.3 Definition of the CDRs and Related Regions *208*
9.4 Antibody Sequence Data *209*
9.4.1 Antibody Sequence Databanks *210*
9.4.2 Germline Sequence Databases *211*
9.4.3 Web Resources for Analyzing Antibody Sequence Data *211*
9.4.3.1 Kabat Data *211*
9.4.3.2 IMGT Data *212*
9.5 Antibody Structure Data *213*
9.6 Screening New Antibody Sequences *213*
9.6.1 Tools for Assigning Subgroups *213*
9.6.2 Identifying Germline Components *214*
9.6.3 Identifying Unusual Features *214*
9.6.4 Assessing ''Humanness'' of Sequences *214*
9.7 abYsis – An Integrated Antibody Sequence and Structure Resource *215*
9.8 Antibody Structure Prediction *216*
9.8.1 Build the Framework *216*
9.8.2 Build the CDRs *216*
9.8.3 Automated Modeling Tools *217*
9.9 Sequence Families *218*
9.9.1 Families and Subgroups *218*
9.9.2 Human Family Chronology *219*
9.9.2.1 Human Heavy Chain Variable Genes (V_H) *219*
9.9.2.2 Human Light Chain Variable Genes (Vλ and Vκ) *219*
9.9.3 Mouse Family Chronology *220*
9.9.3.1 Mouse Heavy Chain Variable Genes (V_H) *220*
9.9.3.2 Mouse Light Chain Variable Genes (Vκ and Vλ) *220*
9.9.4 Correspondence between Human and Mouse Families *221*

9.9.4.1 Heavy Chain Variable Genes (V_H) *221*
9.9.4.2 Light Chain Variable Genes (Vκ and Vλ) *221*
9.10 Summary *222*
References *223*
Websites *226*

10 How to Use IMGT® for Therapeutic Antibody Engineering *229*
Marie-Paule Lefranc
10.1 Introduction *229*
10.2 Fundamental Information from IMGT-ONTOLOGY Concepts *232*
10.2.1 IDENTIFICATION: IMGT® Standardized Keywords *232*
10.2.2 DESCRIPTION: IMGT® Standardized Labels *233*
10.2.3 CLASSIFICATION: IMGT® Standardized Genes and Alleles *233*
10.2.4 NUMEROTATION: IMGT Unique Numbering and IMGT Colliers de Perles *236*
10.2.4.1 IMGT Unique Numbering for V and C Domains *236*
10.2.4.2 IMGT Collier de Perles *237*
10.3 IMGT® Tools and Databases *241*
10.3.1 IMGT/Collier-de-Perles Tool *241*
10.3.2 IMGT/3Dstructure-DB *241*
10.3.3 IMGT/2Dstructure-DB *244*
10.3.4 IMGT/DomainGapAlign *244*
10.3.5 IMGT/V-QUEST *245*
10.3.6 IMGT/HighV-QUEST *246*
10.4 Examples of IMGT® Web Resources for Antibody Engineering and Humanization *246*
10.4.1 Antibody V Domain Humanization *246*
10.4.1.1 CDR-IMGT Grafting *246*
10.4.1.2 Amino Acid Interactions between FR-IMGT and CDR-IMGT *247*
10.4.2 Only-Heavy-Chain Antibodies *247*
10.4.2.1 Dromedary IgG2 and IgG3 *247*
10.4.2.2 Human Heavy Chain Diseases (HCD) *248*
10.4.2.3 Nurse Shark IgN *248*
10.4.3 IGHG CH Amino Acid Positions *249*
10.4.3.1 N-Linked Glycosylation Site CH2 N84.4 *249*
10.4.3.2 Knobs-into-Holes CH3 T22 and Y86 *249*
10.4.3.3 Interface Ball-and-Socket-Like Joints *251*
10.4.3.4 IGHG1 Alleles and G1m Allotypes *251*
10.5 Conclusions *253*
Acknowledgments *255*
Abbreviations *257*
References *257*
Website *263*

Part II: Modified Antibodies *265*

11 Bispecific Antibodies *267*
Dafne Müller and Roland E. Kontermann
11.1 Introduction *267*
11.2 The Generation of Bispecific Antibodies *268*
11.2.1 Somatic Hybridization *268*
11.2.2 Chemical Conjugation *269*
11.2.3 Recombinant Bispecific Antibody Molecules *271*
11.2.3.1 Small Recombinant Bispecific Antibody Formats Derived from the Variable Domain *272*
11.2.3.2 Recombinant Bispecific Antibody Formats Generated by Fusing an Antigen-Binding Site to an IgG *275*
11.2.3.3 Recombinant Bispecific Antibody Formats Containing Asymmetric Heterodimerization Domains *276*
11.3 Bispecific Antibodies and Retargeting of Effector Cells *278*
11.3.1 Retargeting of Cytotoxic T Lymphocytes *279*
11.3.2 Retargeting of Fc Receptor Bearing Effector Cells *283*
11.4 Bispecific Antibodies and Retargeting of Effector Molecules *285*
11.4.1 Bispecific Antibodies and Radioimmunotherapy *286*
11.4.2 Bispecific Antibodies and Targeting of Toxins and Drugs *288*
11.5 Dual Targeting Strategies with Bispecific Antibodies *289*
11.6 Bispecific Antibodies and Somatic Gene Therapy *291*
11.7 Outlook Update *293*
References *293*

12 Single-Domain Antibodies: An Overview *311*
Carrie Enever, Edward Coulstock, Malgorzata Pupecka-Swider, and Bruce Hamilton
12.1 Introduction *311*
12.2 Historical Perspective *312*
12.2.1 Overview *312*
12.2.2 Companies *312*
12.2.3 Assets in the Clinic *314*
12.3 How are sdAbs Isolated? *314*
12.3.1 Introduction *314*
12.3.2 Single-Domain Antibody Library Generation *317*
12.3.2.1 Immune Library Generation *317*
12.3.2.2 Naïve Library Generation *317*
12.3.2.3 Synthetic Library Generation *317*
12.3.2.4 Transgenic Animals *318*
12.3.3 Selection Technologies *319*
12.3.3.1 Phage Display *319*
12.3.3.2 Yeast and Bacterial Display *319*
12.3.3.3 Alternative Display Methods *320*

12.3.4 Affinity Maturation *321*
12.4 Target Space *321*
12.4.1 Structural Differences *322*
12.4.2 Cryptic and Conformational Epitopes *323*
12.4.3 Routes of Administration *324*
12.4.4 Modularity *324*
12.4.5 Tissue Penetration *325*
12.4.6 Diagnostic Application *325*
12.5 Bi-specifics and Targeted Payloads *326*
12.6 Pharmacokinetics/Biodistribution and Half-Life Extension Technologies *328*
12.6.1 PEGylation *328*
12.6.2 Fc-Fusion *329*
12.6.3 Albumin Binding *330*
12.7 Imaging *332*
12.8 Outlook *334*
Acknowledgments *334*
References *334*

13 Antibody–Drug Conjugates: New Frontier in Cancer Therapeutics *341*
Rajeeva Singh, John M. Lambert, and Ravi V. J. Chari
13.1 Introduction *341*
13.2 Currently Approved ADCs for Cancer Treatment *344*
13.3 Cytotoxic Compounds in ADCs *346*
13.3.1 Microtubule-Targeted Cytotoxic Agents *346*
13.3.2 DNA- or DNA-Topoisomerase-Targeted Cytotoxic Agents *352*
13.4 Linkers in ADCs *353*
13.4.1 Noncleavable Thioether Linkers *354*
13.4.2 Disulfide Linkers *355*
13.4.3 Peptide Linkers *356*
13.4.4 Hydrazone Linkage *356*
13.4.5 Carbonate Linkage *356*
13.4.6 Site of Linkage *357*
13.5 Antibody in ADCs *358*
13.6 Conclusions *358*
References *359*

14 Antibody-Targeted Drugs: From Chemical Immunoconjugates to Recombinant Fusion Proteins *363*
Athanasios Mavratzas, Michaela A.E. Arndt, Stefan Kiesgen, and Jürgen Krauss
14.1 Introduction *363*
14.2 Lessons Learned from Chemical Immunoconjugates *363*
14.2.1 Evolution *363*
14.2.2 Linker Stability *364*

14.2.3 Cross-Linkage Heterogeneity *369*
14.2.4 Characteristics of Target Antigens *370*
14.2.5 Characteristics of Effector Moities *372*
14.3 Recombinant Cytotoxic Fusion Proteins *374*
References *378*

Part III: Emerging Technologies *391*

15 Emerging Technologies for Antibody Selection *393*
Mingyue He and Michael J. Taussig
15.1 Introduction *393*
15.2 Display Technologies *394*
15.3 Antibody Libraries *395*
15.4 Antibody Selection and Maturation *In vitro* *397*
15.5 Linking Antibodies to mRNA: Ribosome and mRNA Display *398*
15.6 Advantages of Ribosome Display *399*
15.7 Ribosome Display Systems *399*
15.7.1 Prokaryotic: E. coli S30 *399*
15.7.2 Eukaryotic: Rabbit Reticulocyte *400*
15.7.3 Ribosome Display Constructs *400*
15.7.4 Monosome versus Polysome Display *401*
15.8 Antibody Generation by Ribosome Display *402*
15.9 Summary *402*
References *402*

16 Anti-Idiotypic Antibodies *407*
Alejandro López-Requena, Oscar R. Burrone, and Rolando Pérez
16.1 Introduction *407*
16.2 Basic Concepts *408*
16.3 Physiological Role of Anti-idiotypic Antibodies *412*
16.3.1 Self/Non-self Discrimination *412*
16.3.2 Therapeutic Effect of the Pool of Intravenous Immunoglobulins (IVIg) on Autoimmune Diseases *413*
16.4 Anti-Idiotypic Antibody Responses *414*
16.5 Anti-Idiotypic Antibodies in Cancer *415*
16.6 Anti-idiotypic Antibodies in Other Diseases *417*
16.7 Concluding Remarks *418*
References *419*

17 Non-Antibody Scaffolds as Alternative Therapeutic Agents *435*
Markus Fiedler and Arne Skerra
17.1 Introduction *435*
17.2 Motivation for Therapeutic Use of Alternative Binding Proteins *437*
17.3 Single Domain Immunoglobulins *448*

17.4 Scaffold Proteins Presenting a Contiguous Hypervariable Loop Region *450*
17.5 Scaffold Proteins for Display of Individual Extended Loops *454*
17.6 Scaffold Proteins Providing a Rigid Secondary Structure Interface *457*
17.7 Non-Antibody Scaffolds Stepping into the Clinic *461*
17.8 Conclusions and Outlook: Therapeutic Potential and Ongoing Developments *463*
References *464*

18 Antibody-Directed Enzyme Prodrug Therapy (ADEPT) *475*
Surinder K. Sharma, Kerry A. Chester and Kenneth D. Bagshawe
18.1 Introduction and Basic Principles of ADEPT *475*
18.2 Pre-clinical Studies *477*
18.2.1 CPG2 and Benzoic Mustard Prodrugs *477*
18.2.2 Other Enzyme/Prodrug Systems *478*
18.2.3 Catalytic Antibodies *478*
18.3 Clinical Studies *479*
18.3.1 F(ab) 2 Fragments Conjugated to CPG2 *479*
18.3.2 Recombinant scFv-CPG2 Fusion Protein *479*
18.4 Immunogenicity *480*
18.5 Important Considerations/Outlook *481*
Acknowledgments *482*
Abbreviations *482*
References *482*

19 Engineered Antibody Domains as Candidate Therapeutics *487*
Weizao Chen, Ponraj Prabakaran, and Dimiter S. Dimitrov
19.1 Introduction *487*
19.2 eAd Structure and Function *489*
19.2.1 V_HH *492*
19.2.2 VNAR *492*
19.2.3 VH and VL *494*
19.2.4 CH2 *495*
19.3 eAd Libraries *495*
19.3.1 Generation of eAd Libraries from Naturally Occurring HCAbs *495*
19.3.2 Generation of Semi-Synthetic and Synthetic eAd Libraries *496*
19.3.3 Generation of eAd Libraries with Grafted *In Vivo* Formed CDRs *497*
19.4 eAds against HIV-1 *498*
19.4.1 eAds to the CoRbs of HIV-1 gp120 *499*
19.4.2 eAds to the CD4bs of HIV-1 gp120 *500*
19.4.3 eAds to the MPER of HIV-1 gp41 *500*
19.4.4 eAds to HIV-1 Coreceptors *501*
19.4.5 Implications for HIV-1 Vaccine Immunogen Design *501*
19.5 eAds Targeting Cancer *502*

19.5.1 eAds for Cancer Imaging *502*
19.5.2 eAds for Cancer Therapy *503*
19.5.2.1 eAds Blocking Cancer Cell Signaling *503*
19.5.2.2 eAds for Cancer Drug Targeting *503*
19.5.2.3 eAds Targeting Cancer-Related Soluble Ligands for Their Irreversible Removal *504*
19.6 eAds against Inflammation *505*
19.6.1 eAds against Rheumatoid Arthritis (RA) *505*
19.6.2 eAds against Inflammatory Bowel Disease (IBD) *507*
19.7 eAds against Hematological Disorders *507*
19.8 Conclusions *508*
Acknowledgments *508*
References *508*

20 Chimeric Antigen Receptors –"CARs" *519*
Ulf Petrausch and Thomas Schirrmann
20.1 Introduction *519*
20.2 Chimeric Antigen Receptors –"CARs" *521*
20.2.1 Antigen Recognition of Antibodies and T Cell Receptors *521*
20.2.2 General Design of Chimeric Immunoglobulin T Cell Receptors *522*
20.2.3 Double Chain CARs *523*
20.2.4 Single-Chain CARs *524*
20.2.5 The First Signal of the CAR *525*
20.2.6 Signal Domains Employing Downstream Signal Molecules *526*
20.2.7 The Transmembrane Domain – More Than Only a Membrane Anchor? *528*
20.2.8 Extracellular Spacer Domains Promote CAR Expression and Function *528*
20.2.9 The Second and Third Signals of the CAR *529*
20.3 Preclinical Studies *530*
20.3.1 Retroviral Gene Transfer into T Lymphocytes *530*
20.3.2 "Naked" Gene Delivery Systems *532*
20.3.3 Enrichment of CAR Transfected Effector Cells *532*
20.3.4 Effector Functions of CAR Gene-Modified Effector Lymphocytes *533*
20.3.5 Memory Function of Redirected T Cells *533*
20.3.6 Animal Models *537*
20.4 Therapeutic Considerations *538*
20.4.1 Adoptive Cellular Immunotherapy *538*
20.4.2 Clinical Studies with CAR-Modified T Lymphocytes *540*
20.5 Perspectives *545*
20.5.1 Tumor Taxis and Application of the CAR^+ Effector Cells *545*
20.5.2 Neovascularization of Solid Tumors – Barrier or Target? *546*
20.5.3 Rejection of Receptor Gene-Modified Effector Lymphocytes *546*
20.6 Conclusions *547*
References *547*

21 **Emerging Alternative Production Systems** *561*
Benjamin Sommer, Holger Laux, Andre Frenzel, and Thomas Jostock
21.1 Introduction *561*
21.2 Production Systems *562*
21.2.1 Prokaryotic Expression Systems *562*
21.2.1.1 *Escherichia coli* *562*
21.2.1.2 *Pseudomonas fluorescens* *564*
21.2.1.3 *Bacillus* Species *564*
21.2.2 Eukaryotic Expression Systems *565*
21.2.2.1 Yeast *565*
21.2.2.2 Filamentous Fungi *569*
21.2.2.3 Insect Cells *570*
21.2.2.4 Mammalian Cells *571*
21.2.2.5 Plants *579*
21.2.2.6 Transgenic Animals *580*
21.3 Outlook *581*
Abbreviations *583*
References *583*

Volume II: Clinical Development of Antibodies

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

Part IV: The Way into the Clinic *601*

22 **Process Development and Manufacturing of Therapeutic Antibodies** *603*
Alexander Jacobi, Barbara Enenkel, Patrick Garidel, Christian Eckermann, Mathias Knappenberger, Ingo Presser, and Hitto Kaufmann

23 **The Immunogenicity of Therapeutic Antibodies** *665*
Melody Sauerborn

24 **Biosimilar Monoclonal Antibodies** *681*
Susanne D. Pippig, Carsten Brockmeyer, and Robert E. Zoubek

25 **Patent Issues Relating to Therapeutic Antibodies** *705*
Barbara Rigby, Michael Braunagel, and Deborah Owen

Part V: Therapeutic Antibody Pipeline *735*

26 **Monoclonal Antibody Cancer Treatments in Phase III Clinical Trials** *737*
Ulf Petrausch and Peter Markus Deckert

27 **Antibodies in Cancer Treatment: Early Clinical Development** *787*
Matthew Zibelman, Hossein Borghaei, and Anthony J. Olszanski

28 **Targeting Angiogenesis by Therapeutic Antibodies** *823*
Onat Kadioglu, Ean Jeong Seo, and Thomas Efferth

29 **Antibodies in Phase III Studies for Immunological Disorders** *851*
Penelope Ward and Mark Bodmer

30 **Monoclonal Antibodies in Phase 1 and 2 Studies for Immunological Disorders** *927*
Frank R. Brennan

31 **MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders** *969*
Frank R. Brennan

32 **T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1079*
Frank R. Brennan

33 **B-Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1115*
Frank R. Brennan

34 **Inhibitors of Leukocyte Adhesion and Migration in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1127*
Frank R. Brennan

35 **Toll-Like Receptor Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1145*
Frank R. Brennan

36 **IgE Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1159*
Frank R. Brennan

37 **Complement Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1165*
Frank R. Brennan

38 **mAbs Targeting Apoptosis, Angiogenesis Inhibitors, and Other mAbs in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1175*
Frank R. Brennan

39 ***In vitro* Studies and Clinical Trials about Monoclonal Antibodies Used in Infectiology** *1195*
Guillaume Desoubeaux

40 **Immunotherapeutics for Neurological Disorders** *1215*
Anne Messer, Kevin Manley, and Cynthia A. Lemere

Part VI: Gaining Marketing Approval *1231*

41 **Regulatory Considerations in the Development of Monoclonal Antibodies for Diagnosis and Therapy** *1233*
Marjorie A. Shapiro, Patrick G. Swann, and M. Stacey Ricci

42 **Regulatory Review: Clinical to Market Transition** *1263*
Gabriele Dallmann

43 **Monoclonal Antibody Nomenclature for Clinical Studies (USA)** *1283*
Stephanie C. Shubat

Volume III: Approved Therapeutic Antibodies

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

Part VII: Approved Therapeutic Antibodies *1289*

44 **Oligoclonal and Polyclonal Antibody Preparations** *1291*
Rishab K. Gupta and Mark C. Glassy

45 **Adalimumab (Humira®)** *1309*
Janice M. Reichert

46 **Alemtuzumab (Lemtrada, MabCampath)** *1323*
Thomas Elter, Michael Hallek, and Janice M. Reichert

47 **Basiliximab (Simulect®) and Daclizumab (Zenapax®)** *1375*
Nadim Mahmud, Burcin Taner, and Nasimul Ahsan

48 **Belimumab (Benlysta®)** *1405*
Pamela M. K Lutalo, Natasha Jordan, Thi-Sau Migone, and David P. D'Cruz

49 **Brentuximab Vedotin (Adcetris®) for the Treatment of CD30-Positive Hematologic Malignancies** *1417*
Niels W.C.J. van de Donk and Eugen Dhimolea

50 **Canakinumab (ILARIS®)** *1445*
Hermann Gram

51 **Catumaxomab (Removab) –Trifunctional Antibodies: Combining Direct Tumor Cell Killing with Therapeutic Vaccination** *1463*
Horst Lindhofer, Michael Stanglmaier, Raymund Buhmann, Michael Jäger, Daniel Klunker, Peter Ruf, and Juergen Hess

52 **Cetuximab (Erbitux)** *1501*
Sonja Wilke and Michael Hust

53 **Denosumab (Prolia®)** *1521*
Torsten Meyer

54 **Efalizumab (Raptiva)** *1531*
Karlheinz Schmitt-Rau

55 **Calicheamicin Conjugates: Gemtuzumab Ozogamicin (Mylotarg), Inotuzumab Ozogamicin** *1545*
Matthias Peipp and Martin Gramatzki

56 **Golimumab (Simponi®)** *1565*
Sohini Mazumdar and Janice M. Reichert

57 **Yttrium-90 Ibritumomab Tiuxetan (Zevalin®)** *1579*
Karin Hohloch, Björn Chapuy, and Lorenz Trümper

58 **Infliximab (Remicade®)** *1599*
Christian Antoni and Maria Wiekowski

59 **Ipilimumab (Yervoy®)** *1619*
Teresa Alonso Gordoa, Javier Puente Vázquez, and Eduardo Díaz-Rubio

60 **Muromonab-CD3 (Orthoclone OKT®3)** *1645*
Harald Becker and Janice M. Reichert

61 **Nimotuzumab: A Humanized Anti-EGFR Antibody** *1679*
Tania Crombet Ramos

62 **Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma** *1695*
Christian Klein, Marina Bacac, Pablo Umaña, and Michael Wenger

Volume IV: Approved Therapeutic Antibodies and in vivo Diagnostics

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

63 **Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity** *1733*
Margaret A. Lindorfer, Joost M. Bakker, Paul W.H.I. Parren, and Ronald P. Taylor

64 **Omalizumab (Xolair) – Anti-Immunoglobulin E Treatment in Allergic Diseases** *1775*
Claus Kroegel and Martin Foerster

65 **Palivizumab (Synagis®)** *1825*
Louis Bont

66 **Panitumumab (Vectibix®): A Treatment for Metastatic Colorectal Cancer** *1855*
Jonas Kügler

67 **Pertuzumab (Perjeta®)** *1871*
Jose Angel García-Saénz, Fernando Moreno Anton, and Coralia Bueno Muiño

68 **Ranibizumab (Lucentis): a New Anti-Angiogenic Treatment in Ophthalmology** *1883*
Nicolas Leveziel, Marc Ohresser, and Gilles Paintaud

69 **Raxibacumab, Human Monoclonal Antibody against Anthrax Toxin** *1899*
Sally D. Bolmer and Thi-Sau Migone

70 **Rituximab (Rituxan®)** *1909*
Axel Böhnke and Michael Wenger

71 **Tocilizumab (Actemra®)** *2023*
Graeme Jones and Changhai Ding

72 **Trastuzumab (Herceptin®) and Ado-Trastuzumab Emtansine (Kadcyla®): Treatments for HER2-Positive Breast Cancer** *2041*
Ruhe Chowdhury and Paul Ellis

73 **Ustekinumab (Stelara®)** *2069*
Oya Cingoz, Stefan Dübel, and Janice M. Reichert

74 **Abciximab (Reopro®), Bevacizumab (Avastin®), Certolizumab Pegol (Cimzia®), Eculizumab (Soliris®), Natalizumab (Tysabri®)** *2087*
Janice M. Reichert

75 **Itolizumab (Alzumab®), Mogamulizumab (Poteligeo®), and Tositumomab (Bexxar®)** *2113*
Stefan Dübel

Part VIII: In vivo Diagnostics *2121*

76 **Radiolabeled Antibodies for Diagnostic Imaging** *2123*
Christopher J. Palestro

Index *2143*

Contents

Volume I: Defining the Right Antibody Composition

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

1 **Therapeutic Antibodies – from Past to Future** *1*
Stefan Dübel and Janice M. Reichert

Part I: Selecting and Shaping the Antibody Molecule *15*

2 **Selection Strategies for Monoclonal Antibodies** *17*
Gerhard Moldenhauer

3 **Antibody Phage Display** *43*
Michael Hust, André Frenzel, Florian Tomszak, Jonas Kügler, and Stefan Dübel

4 **Transgenic Animals Derived by DNA Microinjection** *77*
Marianne Brüggemann, Michael J. Osborn, Biao Ma, Suzanne Avis, Ignacio Anegon, and Roland Buelow

5 **Humanization Strategies** *89*
José W. Saldanha

6 **Antibody Affinity** *115*
André Frenzel, Lorin Roskos, Scott Klakamp, Meina Liang, Rosalin Arends, and Larry Green

7 **Fc Engineering** *141*
Matthias Peipp, Stefanie Derer, Stefan Lohse, Christian Kellner, and Thomas Valerius

8 **Glycosylation of Antibody Molecules** *171*
Roy Jefferis

9 **Bioinformatics Tools for Analysis of Antibodies** *201*
Andrew C.R. Martin and James Allen

10 **How to Use IMGT® for Therapeutic Antibody Engineering** *229*
Marie-Paule Lefranc

Part II: Modified Antibodies *265*

11 **Bispecific Antibodies** *267*
Dafne Müller and Roland E. Kontermann

12 **Single-Domain Antibodies: An Overview** *311*
Carrie Enever, Edward Coulstock, Malgorzata Pupecka-Swider, and Bruce Hamilton

13 **Antibody–Drug Conjugates: New Frontier in Cancer Therapeutics** *341*
Rajeeva Singh, John M. Lambert, and Ravi V. J. Chari

14 **Antibody-Targeted Drugs: From Chemical Immunoconjugates to Recombinant Fusion Proteins** *363*
Athanasios Mavratzas, Michaela A.E. Arndt, Stefan Kiesgen, and Jürgen Krauss

Part III: Emerging Technologies *391*

15 **Emerging Technologies for Antibody Selection** *393*
Mingyue He and Michael J. Taussig

16 **Anti-Idiotypic Antibodies** *407*
Alejandro López-Requena, Oscar R. Burrone, and Rolando Pérez

17 **Non-Antibody Scaffolds as Alternative Therapeutic Agents** *435*
Markus Fiedler and Arne Skerra

18 **Antibody-Directed Enzyme Prodrug Therapy (ADEPT)** *475*
Surinder K. Sharma, Kerry A. Chester and Kenneth D. Bagshawe

19 **Engineered Antibody Domains as Candidate Therapeutics** *487*
Weizao Chen, Ponraj Prabakaran, and Dimiter S. Dimitrov

20 **Chimeric Antigen Receptors –"CARs"** *519*
Ulf Petrausch and Thomas Schirrmann

21 **Emerging Alternative Production Systems** *561*
Benjamin Sommer, Holger Laux, Andre Frenzel, and Thomas Jostock

Volume II: Clinical Development of Antibodies

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

Part IV: The Way into the Clinic *601*

22 **Process Development and Manufacturing of Therapeutic Antibodies** *603*
Alexander Jacobi, Barbara Enenkel, Patrick Garidel, Christian Eckermann, Mathias Knappenberger, Ingo Presser, and Hitto Kaufmann
22.1 Introduction *603*
22.2 Upstream Processing *604*
22.2.1 Expression Systems *605*
22.2.2 Cell Culture Media *614*
22.2.3 Cell Culture Process Design *614*
22.2.4 Cell Culture Process Optimization *617*
22.3 Downstream Processing *618*
22.3.1 Platform Technologies for Downstream Processing of Monoclonal Antibodies *620*
22.3.2 Primary Recovery *622*
22.3.2.1 Ultra/Diafiltration (UF/DF) *622*
22.3.2.2 Affinity Chromatography *622*
22.3.3 Purification and Polishing *623*
22.3.3.1 Hydrophobic Interaction Chromatography *623*
22.3.3.2 Ion-Exchange Chromatography *623*
22.3.3.3 Cation-Exchange Chromatography *624*
22.3.3.4 Anion-Exchange Chromatography *624*
22.3.4 Validation of DNA Removal and Virus Clearance *624*

22.3.4.1 Validation of DNA Removal *624*
22.3.4.2 Virus Clearance *625*
22.3.5 Final UF/DF for Drug Substance Manufacturing *625*
22.3.6 New Trends in Downstream Processing *626*
22.3.6.1 Resins and Ligands *626*
22.3.6.2 Separation Technologies *626*
22.3.7 Downstream Processing Concepts *627*
22.3.7.1 Automation/Miniaturization *627*
22.3.7.2 Disposable and Single-Use Concepts *627*
22.3.7.3 Development Concepts *628*
22.4 Formulation Development *628*
22.4.1 Challenges during Early Drug Product Development Phase of Biopharmaceuticals: Liquid Formulation and Freeze-Dried Formulations *629*
22.4.2 Strategies and Analytical Tools for Drug Product Development *631*
22.4.3 Automation Strategies for Rapid Formulation Development *635*
22.4.4 Stabilization of Liquid Protein Formulations by Excipients *635*
22.4.5 Stabilization of Freeze-Dried Protein Formulations by Excipients *638*
22.4.6 From Low-Concentrated Liquid Formulations (LCLF) to High-Concentrated Liquid Formulations (HCLF) *638*
22.5 Commercial Manufacturing Processes *639*
22.5.1 Introduction *639*
22.5.2 Upstream Manufacturing *640*
22.5.3 Harvest *642*
22.5.4 Downstream Manufacturing *643*
22.5.5 Economy of Scale *645*
22.5.6 Process Characterization and Validation *646*
22.6 Analytics *647*
22.6.1 Protein Characterization and Quality Control Testing *647*
22.6.1.1 Characterization and Physicochemical Properties *647*
22.6.2 Purity, Heterogeneity, Integrity, Impurities, Contaminants, and Potency *647*
22.6.2.1 Purity *647*
22.6.2.2 Carbohydrate Heterogeneity *648*
22.6.2.3 Overall Structural Confirmation *648*
22.6.2.4 Impurities *648*
22.6.2.5 Contaminants *650*
22.6.2.6 Potency *650*
22.6.3 Quality Control Testing *651*
22.6.4 Stability Testing *651*
22.6.5 Comparability and Risk Assessment *653*
22.7 Overall Process Development Strategies and Outlook *654*
Acknowledgments *655*
References *655*

23 The Immunogenicity of Therapeutic Antibodies *665*
Melody Sauerborn
23.1 Introduction *665*
23.2 Immunogenicity and the Immune System *667*
23.3 Factors Influencing Immunogenicity *668*
23.4 Clinical Consequences of Immunogenicity of Abs *671*
23.5 Bioanalytical Assessment of ADAs against Therapeutic Antibodies *671*
23.6 Immunogenicity Prediction Tools *673*
23.7 Reduction of Immunogenicity of Abs *674*
23.8 A Look into the Future –The Rise of Antibody-Based Drugs *675*
23.9 Conclusions *678*
References *678*

24 Biosimilar Monoclonal Antibodies *681*
Susanne D. Pippig, Carsten Brockmeyer, and Robert E. Zoubek
24.1 Introduction *681*
24.2 EU Approach to Biosimilars *682*
24.3 US Biosimilars *684*
24.4 Follow-On Monoclonal Antibodies in Emerging Markets *684*
24.5 Technical Development and Analytical Characterization of Biosimilar Monoclonal Antibodies *685*
24.5.1 Excerpt of Frequently Observed Modifications *687*
24.5.2 Manufacturing Process Development *691*
24.6 Non-Clinical and Clinical Development of Biosimilar Monoclonal Antibodies/Pharmacovigilance and Risk Management *693*
24.6.1 Preclinical Development *694*
24.6.2 Clinical Development *697*
24.6.2.1 Pharmacokinetics and Pharmacodynamics *697*
24.6.2.2 Clinical Efficacy and Safety *699*
24.6.2.3 Pharmacovigilance and Risk Management *701*
Acknowledgments *701*
Abbreviations *701*
References *702*

25 Patent Issues Relating to Therapeutic Antibodies *705*
Barbara Rigby, Michael Braunagel, and Deborah Owen
25.1 Why Patents Matter *705*
25.2 Types of Patent Protection in the Field of Therapeutic Antibodies *706*
25.2.1 Novel Antibodies *707*
25.2.2 Therapeutic Applications of Antibodies *708*
25.2.3 Antibody Modifications *709*
25.2.4 Methodology Patents *710*
25.2.5 Overlapping Portfolios *710*
25.3 Freedom to Operate *711*

25.3.1 Introduction *711*
25.3.2 Exemptions from Infringement *712*
25.3.3 Freedom-to-Operate Search *713*
25.3.4 Freedom-to-Operate Analysis *714*
25.3.5 Strategic Considerations *714*
25.3.6 Antibody Patent Landscape *715*
25.3.6.1 Antigen *717*
25.3.6.2 Antibody Format *717*
25.3.6.3 Functional Enhancements *718*
25.3.6.4 Production Systems *718*
25.4 Protecting New Developments *718*
25.4.1 Patentability *718*
25.4.2 Timelines for a Patent Application and Costs *719*
25.4.3 Filing Strategies *722*
25.5 Management of Own and Third-Party Patents *723*
25.5.1 Patent Ownership *723*
25.5.2 Patent Term *723*
25.5.3 Patent Term Extensions *724*
25.5.4 Other Forms of Exclusivity *724*
25.5.5 Monitoring Patents *725*
25.5.6 Influencing Patent Examination (Third-Party Observations) *725*
25.5.7 Attacking Patents *726*
25.6 Patent Exploitation Options and Business Models *726*
25.6.1 Transactions in Patents *726*
25.6.1.1 Licensing *727*
25.6.1.2 Sale *728*
25.6.2 Business Strategies and Patent Exploitation *729*
25.6.2.1 Fee for Service, Contract Research Organisation (CRO) *729*
25.6.2.2 Partnered Discovery *730*
25.6.2.3 Innovative Companies *730*
25.6.2.4 Generic and Biosimilar Producers *731*
25.6.2.5 Out-Licensing *731*
25.6.3 Funding *731*
25.6.4 Due Diligence *732*
25.7 Outlook *733*
25.8 Reference Materials and Further Reading *734*

Part V: Therapeutic Antibody Pipeline *735*

26 Monoclonal Antibody Cancer Treatments in Phase III Clinical Trials *737*
Ulf Petrausch and Peter Markus Deckert
26.1 Introduction *737*
26.2 Antibodies for Use in Lymphoma and Related Diseases *753*
26.2.1 B-Cellular Non-Hodgkin's Lymphoma *753*

26.2.1.1 Ofatumumab *753*
26.2.1.2 Obinutuzumab *754*
26.2.1.3 Epratuzumab (Anti-CD22) *755*
26.2.1.4 Inotuzumab Ozogamicin (Anti-CD22) *756*
26.2.1.5 Galiximab (Anti-CD80) *757*
26.2.1.6 Elotuzumab (Anti-CS1) *757*
26.2.2 T-Cellular Non-Hodgkin's Lymphoma *758*
26.2.2.1 Zanolimumab (Anti-CD4) *758*
26.2.3 Hodgkin's Lymphoma *759*
26.2.3.1 Brentuximab Vedotin (Anti-CD30–Monomethyl Auristatin E) *759*
26.3 Anti-EpCAM Antibodies: A Lesson in History and What Remains *760*
26.4 Antibodies Against Epithelial Growth Factor Targets *761*
26.4.1 Antibodies against EGFR *761*
26.4.2 Trastuzumab Emtansine (Her2/Neu) *763*
26.4.3 Ramucirumab (VEGF-R) *764*
26.5 Insulin-Like Growth Factor Type I Receptor Antibodies *765*
26.5.1 Ganitumab *765*
26.5.2 Dalotuzumab *766*
26.5.3 Cixutumumab *766*
26.5.4 Figitumumab *767*
26.6 Antibodies for Use in Renal Cell Carcinoma *767*
26.6.1 Girentuximab (Carbonic Anhydrase IX) *767*
26.6.2 Naptumomab Estafenatox (5T4) *768*
26.7 Antibodies for Use in Ovarian Cancer *769*
26.7.1 Farletuzumab *769*
26.7.2 Oregovomab *769*
26.8 Blockage of Immunological Checkpoints *770*
26.8.1 Ipilimumab (Anti-CTLA4) *771*
26.8.2 Nivolumab (Anti-PD1) *772*
26.9 Miscellaneous Diseases and Targets *773*
26.9.1 Rilotumumab *773*
26.9.2 Onartuzumab *773*
26.9.3 Racotumomab *774*
26.9.4 Pemtumomab *775*
26.9.5 Denosumab *775*
26.10 Summary *776*
References *777*

27 Antibodies in Cancer Treatment: Early Clinical Development *787*
Matthew Zibelman, Hossein Borghaei, and Anthony J. Olszanski
27.1 Introduction *787*
27.2 Harnessing Innate Immunity *788*
27.2.1 Antibody-Dependent Cytotoxicity *789*
27.2.2 Complement-Dependent Cytotoxicity *791*

27.2.3 Immunomodulating Antibodies *792*
27.3 Alteration of Intracellular Signaling *795*
27.3.1 Ligand Inhibition *796*
27.3.2 Ligand-Dependent Cell Receptor Inhibition *798*
27.3.3 Ligand-Independent Alteration of Signal Transduction *800*
27.4 Immunoconjugates *802*
27.4.1 Antibody-Drug Conjugates *804*
27.4.2 Radioimmunoconjugates *806*
27.4.3 Bispecific Antibodies and Bispecific T-Cell Engagers (BiTEs) *807*
27.5 The Three U's: Mechanisms of Unique, Unclear, or Unknown Function *809*
27.5.1 Unclear or Unknown Mechanisms *809*
27.5.2 Unique Mechanisms *811*
27.6 Summary *812*
References *813*

28 Targeting Angiogenesis by Therapeutic Antibodies *823*
Onat Kadioglu, Ean Jeong Seo, and Thomas Efferth
28.1 Introduction *823*
28.1.1 Angiogenesis in Cancer Development *823*
28.1.2 Angiogenic Switch *824*
28.1.3 Role of Macrophages for Angiogenesis *825*
28.1.4 Molecular Regulators of Angiogenesis *825*
28.1.4.1 Vascular Endothelial Growth Factor (VEGF) *825*
28.1.4.2 Basic Fibroblast Growth Factor (bFGF) *827*
28.1.4.3 Other Angiogenic Stimulators *827*
28.1.4.4 Angiogenesis Inhibitors *828*
28.1.5 Damaged Vessels Favor Angiogenesis *830*
28.2 Therapeutic Antibodies *830*
28.2.1 Targeting the EGF and VEGF Pathways *831*
28.2.2 Targeting VEGF Ligand *833*
28.2.3 Multiple Signaling Routes of VEGF *835*
28.2.3.1 Antibodies *835*
28.2.3.2 Fusion Constructs *835*
28.2.3.3 Resistance Mechanisms *836*
28.2.4 Targeting Other Angiogenesis Components *836*
28.2.4.1 Angiopoietin Type 2 *836*
28.2.4.2 Angiotensin-2 Receptor *837*
28.2.4.3 Integrins *837*
28.2.4.4 Cadherins *838*
28.2.4.5 Targeting MET Tyrosine Kinase *838*
28.2.4.6 Extracellular Matrix *839*
28.3 Conclusion *841*
Abbreviations *841*
References *843*

29 Antibodies in Phase III Studies for Immunological Disorders *851*
Penelope Ward and Mark Bodmer
29.1 Introduction *851*
29.2 Antibody Targets in Phase III Trials *852*
29.2.1 Catalytic Protease Targets *852*
29.2.1.1 Pro-protein Convertase Subtilisin Kexin (PCSK)-9 *852*
29.2.2 Bone Metabolism Target *859*
29.2.2.1 Sclerostin *859*
29.2.3 Cytokine/Chemokine Targets *866*
29.2.3.1 Interleukin 6 and Interleukin-6 Receptor *866*
29.2.3.2 Interleukin-1β *873*
29.2.3.3 Interleukin-5 *876*
29.2.3.4 Interleukin-13 *883*
29.2.3.5 Interleukin-17A and Interleukin-17A Receptor *885*
29.2.3.6 Interleukin-23 *897*
29.2.4 Adhesion Molecule Targets *899*
29.2.4.1 α4β7 Integrin *899*
29.2.5 Cell-Surface Receptor Targets *901*
29.2.5.1 CD6 *901*
29.2.5.2 CD20 *902*
29.2.5.3 CD22 *904*
29.2.6 Amyloid Protein Targets *905*
29.2.6.1 Amyloid β Protein *905*
29.3 Summary *909*
References *910*

30 Monoclonal Antibodies in Phase 1 and 2 Studies for Immunological Disorders *927*
Frank R. Brennan
30.1 Introduction *927*
30.2 General Overview of the Immune System and Key Pathways Driving Inflammatory Diseases *934*
30.3 Review of the Major Inflammatory Diseases Targeted by mAbs, Goals of Current Therapies and How These Might Be Met by Existing and Emerging Biologics *936*
30.3.1 Rheumatoid Arthritis *936*
30.3.2 Psoriasis and Psoriatic Arthritis *937*
30.3.3 Inflammatory Bowel Disease *938*
30.3.4 Multiple Sclerosis *939*
30.3.5 Systemic Lupus Erythrematosus *941*
30.3.6 Ocular Diseases (Uveitis and Age-Related Macular Degeneration (AMD)) *943*
30.3.6.1 Uveitis *943*
30.3.6.2 Age-Related Macular Degeneration (AMD) *944*
30.3.7 Allergic Diseases: Asthma and Atopic Dermatitis *945*

30.3.7.1 Asthma *945*
30.3.7.2 Atopic Dermatitis *948*
30.3.8 Diabetes *949*
30.3.8.1 Type 1 Diabetes *949*
30.3.8.2 Type II Diabetes *950*
30.3.9 Organ Transplantation – Graft Rejection *951*
30.3.10 Other Immunological Diseases *953*
30.4 Mechanisms of Target Modulation Utilized by Monoclonal Antibodies *954*
30.5 Optimizing mAbs for Efficacy and Safety *954*
30.6 Summary *956*
References *957*

31 MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders *969*
Frank R. Brennan
31.1 Introduction *969*
31.1.1 MAbs Targeting Soluble Mediators *970*
31.1.1.1 Cytokine Inhibitors *970*
31.1.1.2 Chemokine Inhibitors *1015*
31.1.1.3 Growth Factor Inhibitors *1023*
References *1028*

32 T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders *1079*
Frank R. Brennan
32.1 Introduction *1079*
32.2 T-Cell Inhibitors *1079*
32.2.1 Anti-T Cell Rαβ *1079*
32.2.2 Anti-CD3 *1081*
32.2.3 Anti-CD4 *1083*
32.2.4 Anti-CD100 (Semaphorin 4D) *1085*
32.3 Anti-T-Cell Costimulators *1086*
32.3.1 Anti-CD28 *1087*
32.3.2 Anti-ICOSL (B7RP-1) *1088*
32.3.3 Anti-OX40/OX40L *1091*
32.3.4 Anti-HVEM/LIGHT *1093*
32.3.5 Anti-CD26 (DPPIV) *1095*
32.3.6 Anti-NKG2A *1097*
References *1098*

33 B-Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders *1115*
Frank R. Brennan
33.1 Introduction *1115*

33.2 Anti-CD19 *1115*
33.3 Anti-BAFF (Blys) *1117*
33.4 Anti-CD20 *1119*
References *1121*

34 Inhibitors of Leukocyte Adhesion and Migration in Phase 1 and 2 Clinical Studies for Immunological Disorders *1127*
Frank R. Brennan
34.1 Introduction *1127*
34.2 Inhibitors of Leukocyte Adhesion and Migration *1128*
34.2.1 Anti-α4β7/MAdCAM-1 *1128*
34.2.2 Anti-α1β1 Integrin (VLA-1) *1131*
34.2.3 Anti-α2β1 Integrin (VLA-2) *1133*
34.2.4 Anti-VAP-1 *1134*
34.2.5 Anti-CD162 (P-Selectin Glycoprotein Ligand; PSGL-1) *1136*
References *1138*

35 Toll-Like Receptor Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders *1145*
Frank R. Brennan
35.1 Introduction *1145*
35.2 Toll-Like Receptor Inhibitors *1146*
35.2.1 Anti-TLR2 *1146*
35.2.2 Anti-TLR3 *1147*
35.2.3 Anti-TLR4 *1149*
References *1151*

36 IgE Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders *1159*
Frank R. Brennan
36.1 Introduction *1159*
36.2 IgE Inhibitors *1161*
36.2.1 Anti-IgE *1161*
36.2.2 Anti-IgE M1′ *1162*
References *1163*

37 Complement Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders *1165*
Frank R. Brennan
37.1 Introduction *1165*
37.2 Complement Inhibitors *1166*
37.2.1 Anti-C5/C5a/C5aR *1166*
37.2.2 Anti-Factor D *1169*
References *1171*

38 **mAbs Targeting Apoptosis, Angiogenesis Inhibitors, and Other mAbs in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1175*
Frank R. Brennan
38.1 mAbs Targeting Apoptosis *1175*
38.1.1 Anti-Fas (CD95) *1175*
38.2 Angiogenesis Inhibitors *1177*
38.2.1 Anti-VEGF *1177*
38.2.2 Anti-S1P *1178*
38.3 Other mAbs *1181*
38.3.1 Anti-MMP-9 *1181*
38.3.2 Anti-LINGO-1 *1182*
38.3.3 Anti-MRSV env *1183*
38.3.4 Anti-fibronectin-IL-10 Fusion Protein *1185*
References *1185*

39 ***In vitro* Studies and Clinical Trials about Monoclonal Antibodies Used in Infectiology** *1195*
Guillaume Desoubeaux
39.1 Introduction and Infectious Context *1195*
39.2 Historical of Antibodies Used in Infectiology and Previous Clinical Trials *1196*
39.3 General Mechanisms of Action *1196*
39.4 Mode of Production of Anti-Infectious Antibodies *1197*
39.5 Anti-Infectious Monoclonal Antibodies Against Bacteria and Associated Toxins *1197*
39.6 Viral Diseases and Anti-Infectious Monoclonal Antibodies *1201*
39.7 Perspectives and Future Development of Antimycotic Monoclonal Antibodies *1207*
39.8 Conclusion *1207*
Acknowledgments *1207*
Author Contributions *1208*
Funding *1208*
Transparency Declarations Sections and Conflicts of Interest *1208*
References *1208*

40 **Immunotherapeutics for Neurological Disorders** *1215*
Anne Messer, Kevin Manley, and Cynthia A. Lemere
40.1 Introduction *1215*
40.1.1 Overview of Advantages and Challenges of Immunotherapy for Neurological Diseases *1215*
40.1.2 Neurological Disease Targets *1216*
40.1.3 Active Versus Passive Immunotherapy *1216*
40.2 Alzheimer's Disease *1217*
40.2.1 Disease and Target *1217*
40.2.2 Active Immunotherapy for Aβ *1218*

40.2.3 Passive Immunotherapy for Aβ *1218*
40.2.4 Immunotherapy Directed at Aβ-Related Targets *1220*
40.2.5 Immunotherapy Directed at Tau *1220*
40.3 Parkinson's Disease and Dementia with Lewy Bodies *1220*
40.3.1 Disease and Targets *1220*
40.3.1.1 Active Immunotherapy – Preclinical *1221*
40.3.1.2 Active Immunotherapy – Clinical *1221*
40.3.2 Passive Immunotherapy *1221*
40.3.2.1 Passive Immunotherapy with Full-Length Antibody *1221*
40.3.2.2 Passive Immunotherapy with Intrabodies *1221*
40.4 Huntington's Disease *1222*
40.4.1 Disease and Target *1222*
40.4.2 Passive Immunotherapy with Intrabodies *1222*
40.4.3 Active Immunotherapy with DNA Vaccines *1223*
40.5 Amyotrophic Lateral Sclerosis *1223*
40.5.1 Disease and Target *1223*
40.5.2 Active Immunotherapy *1224*
40.5.3 Passive Immunotherapy *1224*
40.6 Transmissible Spongiform Encephalopathies *1224*
40.6.1 Disease and Target *1224*
40.6.2 Active Immunotherapy *1225*
40.6.3 Passive Immunotherapy *1225*
40.7 Conclusion *1225*
Acknowledgments *1226*
References *1226*

Part VI: Gaining Marketing Approval *1231*

41 Regulatory Considerations in the Development of Monoclonal Antibodies for Diagnosis and Therapy *1233*
Marjorie A. Shapiro, Patrick G. Swann, and M. Stacey Ricci
41.1 Introduction *1233*
41.2 Regulatory Authority *1237*
41.3 Chemistry, Manufacturing, and Controls Considerations *1240*
41.3.1 Cell Line Qualification *1240*
41.3.2 Quality Control Testing *1242*
41.3.3 Transmissible Spongiform Encephalopathy (TSE) *1244*
41.3.4 Product Stability *1245*
41.3.5 Reference Standard *1245*
41.3.6 Viral Clearance and Inactivation Studies *1246*
41.3.7 Abbreviated Product Safety Testing for Feasibility Trials in Serious or Immediately Life-Threatening Conditions *1246*
41.3.8 Comparability *1247*
41.3.9 Quality by Design *1248*
41.4 Considerations for Nonclinical Testing *1249*

41.4.1 Components of a Nonclinical Safety Testing Program *1250*
41.4.2 Relevant Species *1251*
41.4.3 Pharmacology and Pharmacokinetic Studies *1252*
41.4.4 Toxicology *1254*
41.5 Immunogenicity *1255*
41.5.1 Nonclinical *1255*
41.5.2 Clinical *1256*
41.6 Conclusions *1257*
Acknowledgments *1258*
References *1258*

42 Regulatory Review: Clinical to Market Transition *1263*
Gabriele Dallmann
42.1 Introduction *1263*
42.2 General Considerations for the Clinical Development of mAbs *1264*
42.3 The Need for Regulatory Validation of the Development Program *1266*
42.4 The Approach of Agencies for Clinical Review of mAb *1266*
42.4.1 Clinical Review Approach *1266*
42.4.2 Approval Timelines *1267*
42.4.3 Fast Approval – When the Data Are Compelling *1268*
42.5 Strategic Regulatory Options for Rapid Market Access *1270*
42.6 Pivotal Clinical Trials for mAb *1271*
42.7 Specific Considerations for Early Development Clinic Studies of mAb *1272*
42.7.1 Scope of Comparability Investigations During Clinical Development and the Life Cycle of mAbs *1275*
42.7.2 Pre-authorization Interactions with Agencies – The Scientific Advice Procedure *1276*
42.7.3 Clinical Trial Authorization of mAb *1277*
42.7.4 Risk Management Plan *1278*
42.7.5 mAb Typical Post-marketing Activities *1279*
References *1280*

43 Monoclonal Antibody Nomenclature for Clinical Studies (USA) *1283*
Stephanie C. Shubat
43.1 Elements of a Name *1283*
43.2 Sequence of Stems and Infixes *1284*
43.2.1 Prefix *1284*
43.3 Target/Disease Class Infix *1284*
43.3.1 Source Infix *1285*
43.4 USAN Modified Designations for Monoclonal Antibodies *1286*
43.5 Required Application Information *1287*

Volume III: Approved Therapeutic Antibodies

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

Part VII: Approved Therapeutic Antibodies *1289*

44 **Oligoclonal and Polyclonal Antibody Preparations** *1291*
Rishab K. Gupta and Mark C. Glassy

45 **Adalimumab (Humira®)** *1309*
Janice M. Reichert

46 **Alemtuzumab (Lemtrada, MabCampath)** *1323*
Thomas Elter, Michael Hallek, and Janice M. Reichert

47 **Basiliximab (Simulect®) and Daclizumab (Zenapax®)** *1375*
Nadim Mahmud, Burcin Taner, and Nasimul Ahsan

48 **Belimumab (Benlysta®)** *1405*
Pamela M. K Lutalo, Natasha Jordan, Thi-Sau Migone, and David P. D'Cruz

49 **Brentuximab Vedotin (Adcetris®) for the Treatment of CD30-Positive Hematologic Malignancies** *1417*
Niels W.C.J. van de Donk and Eugen Dhimolea

50 **Canakinumab (ILARIS®)** *1445*
Hermann Gram

51 **Catumaxomab (Removab) – Trifunctional Antibodies: Combining Direct Tumor Cell Killing with Therapeutic Vaccination** *1463*
Horst Lindhofer, Michael Stanglmaier, Raymund Buhmann, Michael Jäger, Daniel Klunker, Peter Ruf, and Juergen Hess

52 **Cetuximab (Erbitux)** *1501*
Sonja Wilke and Michael Hust

53 **Denosumab (Prolia®)** *1521*
Torsten Meyer

54 **Efalizumab (Raptiva)** *1531*
Karlheinz Schmitt-Rau

55 **Calicheamicin Conjugates: Gemtuzumab Ozogamicin (Mylotarg), Inotuzumab Ozogamicin** *1545*
Matthias Peipp and Martin Gramatzki

56 **Golimumab (Simponi®)** *1565*
Sohini Mazumdar and Janice M. Reichert

57 **Yttrium-90 Ibritumomab Tiuxetan (Zevalin®)** *1579*
Karin Hohloch, Björn Chapuy, and Lorenz Trümper

58 **Infliximab (Remicade®)** *1599*
Christian Antoni and Maria Wiekowski

59 **Ipilimumab (Yervoy®)** *1619*
Teresa Alonso Gordoa, Javier Puente Vázquez, and Eduardo Díaz-Rubio

60 **Muromonab-CD3 (Orthoclone OKT®3)** *1645*
Harald Becker and Janice M. Reichert

61 **Nimotuzumab: A Humanized Anti-EGFR Antibody** *1679*
Tania Crombet Ramos

62 **Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma** *1695*
Christian Klein, Marina Bacac, Pablo Umaña, and Michael Wenger

Volume IV: Approved Therapeutic Antibodies and in vivo Diagnostics

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

63 **Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity** *1733*
Margaret A. Lindorfer, Joost M. Bakker, Paul W.H.I. Parren, and Ronald P. Taylor

64 **Omalizumab (Xolair) – Anti-Immunoglobulin E Treatment in Allergic Diseases** *1775*
Claus Kroegel and Martin Foerster

65 **Palivizumab (Synagis®)** *1825*
Louis Bont

66 **Panitumumab (Vectibix®): A Treatment for Metastatic Colorectal Cancer** *1855*
Jonas Kügler

67 **Pertuzumab (Perjeta®)** *1871*
Jose Angel García-Saénz, Fernando Moreno Anton, and Coralia Bueno Muiño

68 **Ranibizumab (Lucentis): a New Anti-Angiogenic Treatment in Ophthalmology** *1883*
Nicolas Leveziel, Marc Ohresser, and Gilles Paintaud

69 **Raxibacumab, Human Monoclonal Antibody against Anthrax Toxin** *1899*
Sally D. Bolmer and Thi-Sau Migone

70 **Rituximab (Rituxan®)** *1909*
Axel Böhnke and Michael Wenger

71 **Tocilizumab (Actemra®)** *2023*
Graeme Jones and Changhai Ding

72 **Trastuzumab (Herceptin®) and Ado-Trastuzumab Emtansine (Kadcyla®): Treatments for HER2-Positive Breast Cancer** *2041*
Ruhe Chowdhury and Paul Ellis

73 **Ustekinumab (Stelara®)** *2069*
Oya Cingoz, Stefan Dübel, and Janice M. Reichert

74 **Abciximab (Reopro®), Bevacizumab (Avastin®), Certolizumab Pegol (Cimzia®), Eculizumab (Soliris®), Natalizumab (Tysabri®)** *2087*
Janice M. Reichert

75 **Itolizumab (Alzumab®), Mogamulizumab (Poteligeo®), and Tositumomab (Bexxar®)** *2113*
Stefan Dübel

Part VIII: In vivo Diagnostics *2071*

76 **Radiolabeled Antibodies for Diagnostic Imaging** *2123*
Christopher J. Palestro

Index *2143*

Contents

Volume I: Defining the Right Antibody Composition

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

1 **Therapeutic Antibodies – from Past to Future** *1*
Stefan Dübel and Janice M. Reichert

Part I: Selecting and Shaping the Antibody Molecule *15*

2 **Selection Strategies for Monoclonal Antibodies** *17*
Gerhard Moldenhauer

3 **Antibody Phage Display** *43*
Michael Hust, André Frenzel, Florian Tomszak, Jonas Kügler, and Stefan Dübel

4 **Transgenic Animals Derived by DNA Microinjection** *77*
Marianne Brüggemann, Michael J. Osborn, Biao Ma, Suzanne Avis, Ignacio Anegon, and Roland Buelow

5 **Humanization Strategies** *89*
José W. Saldanha

6 **Antibody Affinity** *115*
André Frenzel, Lorin Roskos, Scott Klakamp, Meina Liang, Rosalin Arends, and Larry Green

7 **Fc Engineering** *141*
Matthias Peipp, Stefanie Derer, Stefan Lohse, Christian Kellner, and Thomas Valerius

8 **Glycosylation of Antibody Molecules** *171*
Roy Jefferis

9 **Bioinformatics Tools for Analysis of Antibodies** *201*
Andrew C.R. Martin and James Allen

Part II: Modified Antibodies *265*

11 **Bispecific Antibodies** *267*
Dafne Müller and Roland E. Kontermann

12 **Single-Domain Antibodies: An Overview** *311*
Carrie Enever, Edward Coulstock, Malgorzata Pupecka-Swider, and Bruce Hamilton

13 **Antibody–Drug Conjugates: New Frontier in Cancer Therapeutics** *341*
Rajeeva Singh, John M. Lambert, and Ravi V. J. Chari

14 **Antibody-Targeted Drugs: From Chemical Immunoconjugates to Recombinant Fusion Proteins** *363*
Athanasios Mavratzas, Michaela A.E. Arndt, Stefan Kiesgen, and Jürgen Krauss

Part III: Emerging Technologies *391*

15 **Emerging Technologies for Antibody Selection** *393*
Mingyue He and Michael J. Taussig

16 **Anti-Idiotypic Antibodies** *407*
Alejandro López-Requena, Oscar R. Burrone, and Rolando Pérez

17 **Non-Antibody Scaffolds as Alternative Therapeutic Agents** *435*
Markus Fiedler and Arne Skerra

18 **Antibody-Directed Enzyme Prodrug Therapy (ADEPT)** *475*
Surinder K. Sharma, Kerry A. Chester and Kenneth D. Bagshawe

19 **Engineered Antibody Domains as Candidate Therapeutics** *487*
Weizao Chen, Ponraj Prabakaran, and Dimiter S. Dimitrov

20 **Chimeric Antigen Receptors –"CARs"** *519*
Ulf Petrausch and Thomas Schirrmann

21 **Emerging Alternative Production Systems** *561*
Benjamin Sommer, Holger Laux, Andre Frenzel, and Thomas Jostock

Volume II: Clinical Development of Antibodies

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

Part IV: The Way into the Clinic *601*

22 **Process Development and Manufacturing of Therapeutic Antibodies** *603*
Alexander Jacobi, Barbara Enenkel, Patrick Garidel, Christian Eckermann, Mathias Knappenberger, Ingo Presser, and Hitto Kaufmann

23 **The Immunogenicity of Therapeutic Antibodies** *665*
Melody Sauerborn

24 **Biosimilar Monoclonal Antibodies** *681*
Susanne D. Pippig, Carsten Brockmeyer, and Robert E. Zoubek

25 **Patent Issues Relating to Therapeutic Antibodies** *705*
Barbara Rigby, Michael Braunagel, and Deborah Owen

Part V: Therapeutic Antibody Pipeline *735*

26 **Monoclonal Antibody Cancer Treatments in Phase III Clinical Trials** *737*
Ulf Petrausch and Peter Markus Deckert

27 **Antibodies in Cancer Treatment: Early Clinical Development** *787*
Matthew Zibelman, Hossein Borghaei, and Anthony J. Olszanski

28 **Targeting Angiogenesis by Therapeutic Antibodies** *823*
Onat Kadioglu, Ean Jeong Seo, and Thomas Efferth

29 **Antibodies in Phase III Studies for Immunological Disorders** *851*
Penelope Ward and Mark Bodmer

30 **Monoclonal Antibodies in Phase 1 and 2 Studies for Immunological Disorders** *927*
Frank R. Brennan

31 **MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders** *969*
Frank R. Brennan

32 **T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1079*
Frank R. Brennan

33 **B-Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1115*
Frank R. Brennan

34 **Inhibitors of Leukocyte Adhesion and Migration in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1127*
Frank R. Brennan

35 **Toll-Like Receptor Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1145*
Frank R. Brennan

36 **IgE Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1159*
Frank R. Brennan

37 **Complement Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1165*
Frank R. Brennan

38 **mAbs Targeting Apoptosis, Angiogenesis Inhibitors, and Other mAbs in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1175*
Frank R. Brennan

39 ***In vitro* Studies and Clinical Trials about Monoclonal Antibodies Used in Infectiology** *1195*
Guillaume Desoubeaux

40 **Immunotherapeutics for Neurological Disorders** *1215*
Anne Messer, Kevin Manley, and Cynthia A. Lemere

Part VI: Gaining Marketing Approval *1231*

41 **Regulatory Considerations in the Development of Monoclonal Antibodies for Diagnosis and Therapy** *1233*
Marjorie A. Shapiro, Patrick G. Swann, and M. Stacey Ricci

42 **Regulatory Review: Clinical to Market Transition** *1263*
Gabriele Dallmann

43 **Monoclonal Antibody Nomenclature for Clinical Studies (USA)** *1283*
Stephanie C. Shubat

Volume III: Approved Therapeutic Antibodies

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

Part VII: Approved Therapeutic Antibodies *1289*

44 **Oligoclonal and Polyclonal Antibody Preparations** *1291*
Rishab K. Gupta and Mark C. Glassy
44.1 Introduction *1291*
44.2 Oligoclonal Antibodies *1291*
44.3 General Questions/Concerns *1293*
44.4 Uses/Applications of Oligoclonal Antibodies *1293*
44.5 Infectious Disease *1295*
44.5.1 Virology *1295*
44.5.2 Cancer *1295*
44.6 FDA/Regulatory Considerations *1295*
44.7 Polyclonal Antibodies *1296*
44.8 Production of Polyclonal Antibodies *1297*
44.9 Immunogen Properties and Preparations *1298*
44.10 Carrier Proteins for Immunogen Preparation *1298*
44.11 Choice of Animal *1299*
44.12 Adjuvants *1299*
44.13 Route of Injection *1300*
44.14 Collecting and Processing of Blood *1300*
44.15 Antibody Purification *1300*

44.16 Polyclonal Antibody Derives Therapeutics (Clinical Utility) *1301*
44.17 Recombinant Polyclonal Antibodies *1302*
44.18 Summary *1303*
References *1304*

45 Adalimumab (Humira®) *1309*
Janice M. Reichert
45.1 Overview *1309*
45.2 Basic Principles of Clinical Use *1310*
45.3 Safety *1310*
45.4 Use in Approved Indications *1312*
45.5 Clinical Studies in Intestinal Behçet Disease *1313*
45.6 Clinical Studies in Uveitis *1314*
45.7 Clinical Studies in Hidradenitis Suppurativa *1316*
45.8 Early-Stage Clinical Studies in Sarcoidosis *1318*
References *1319*

46 Alemtuzumab (Lemtrada, MabCampath) *1323*
Thomas Elter, Michael Hallek, and Janice M. Reichert
46.1 Overview *1323*
46.2 Basic Principles *1324*
46.3 Antibody Features and Production *1324*
46.4 Molecular Target and Target Expression *1325*
46.5 Mechanism of Cell Lysis *1327*
46.6 Immunogenicity and Antiglobulin Response *1328*
46.7 Pharmacokinetic Studies *1329*
46.8 Clinical Studies in Chronic Lymphocytic Leukemia (CLL) *1330*
46.8.1 Relapsed/Refractory CLL *1330*
46.8.2 Minimal Residual Disease in CLL *1336*
46.8.3 Treatment-Naive CLL *1338*
46.8.3.1 Chemoimmunotherapy Combinations *1339*
46.8.3.2 Immunotherapy Combination *1342*
46.8.4 Safety of Alemtuzumab in CLL *1343*
46.8.4.1 Infusion-Related Adverse Events *1343*
46.8.4.2 Hematologic Toxicities *1344*
46.8.4.3 Immunosuppression and Infectious Events *1346*
46.9 Clinical Studies in Multiple Sclerosis *1347*
46.10 Clinical Studies in Other Indications *1353*
46.10.1 T-Cell Lymphomas (Cutaneous/Peripheral T-Cell Lymphoma) *1353*
46.10.2 T-Cell Prolymphocytic Leukemia (T-PLL) *1355*
46.10.3 Adult T-Cell Leukemia *1356*
46.10.4 Non-Hodgkin's Lymphoma (NHL) *1357*
46.10.5 Multiple Myeloma and Acute Leukemias *1359*
46.10.6 Rheumatoid Arthritis *1359*

46.10.7 Donor T-Cell Depletion (Prevention of GvHD) and Prevention of Graft Rejection *1360*
46.10.7.1 Reduced-Intensity/Nonmyeloablative Conditioning *1361*
46.10.7.2 Safety *1363*
46.10.7.3 Prevention of GvHD in Solid Organ Transplantation *1363*
References *1365*

47 Basiliximab (Simulect®) and Daclizumab (Zenapax®) *1375*
Nadim Mahmud, Burcin Taner, and Nasimul Ahsan
47.1 Background *1375*
47.1.1 Solid Organ Transplantation and IL-2R-Based Therapy *1377*
47.2 Clinical Use in Human Organ Transplantation *1378*
47.2.1 Renal Transplantation *1378*
47.2.1.1 IL-2R Monoclonal Antibodies versus Placebo *1378*
47.2.1.2 Basiliximab versus Other Lymphocyte-Depleting Agents *1379*
47.2.1.3 Modified-Dose Daclizumab Studies *1379*
47.2.1.4 Steroid-Sparing Protocols *1380*
47.2.1.5 Calcineurin Inhibitor-Sparing Protocols *1381*
47.2.1.6 Basiliximab versus Daclizumab *1382*
47.2.2 Applications in Adult Non-renal Transplantation *1383*
47.2.2.1 Liver *1383*
47.2.2.2 Lung *1385*
47.2.2.3 Heart *1386*
47.2.2.4 Pancreas *1387*
47.3 Clinical Use of IL-2R Antibodies in Non-organ Transplant Conditions *1388*
47.3.1 Multiple Sclerosis *1388*
47.3.2 Adult T-Cell Leukemia *1392*
47.3.3 Tropical Spastic Paraparesis and HTLV-Associated Myelopathy *1393*
47.3.4 Noninfectious Ocular Inflammatory Disease (Uveitis) *1393*
47.3.5 Age-Related Macular Degeneration *1394*
47.3.6 Graft Versus Host Disease *1394*
47.4 Conclusion *1395*
References *1396*

48 Belimumab (Benlysta®) *1405*
Pamela M. K Lutalo, Natasha Jordan, Thi-Sau Migone, and David P. D'Cruz
48.1 Introduction *1405*
48.2 Basic Principles *1405*
48.3 Clinical Aspects of Belimumab Therapy *1407*
48.3.1 Belimumab Clinical Trial Data *1407*
48.3.2 Safety of Belimumab in Clinical Practice *1409*
48.3.2.1 Common Side Effects *1409*
48.3.3 Hypersensitivity Adverse Events *1410*

48.3.4 Immunosuppression-Related Adverse Events *1410*
48.3.5 Malignancy Adverse Events *1410*
48.3.6 Reproduction Adverse Events *1411*
48.3.7 Psychiatric Adverse Events *1411*
48.3.8 Mortality Adverse Events *1411*
48.3.9 New Belimumab Clinical Trials *1411*
48.4 Summary *1413*
List of abbreviations *1413*
References *1414*

49 Brentuximab Vedotin (Adcetris®) for the Treatment of CD30-Positive Hematologic Malignancies *1417*
Niels W.C.J. van de Donk and Eugen Dhimolea
49.1 Introduction *1417*
49.2 CD30 *1418*
49.3 Preclinical Activity of Brentuximab Vedotin *1419*
49.4 Clinical Development of Brentuximab Vedotin *1420*
49.4.1 Hodgkin Lymphoma *1420*
49.4.1.1 Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma *1421*
49.4.1.2 Brentuximab Vedotin Before or After Auto-SCT *1427*
49.4.1.3 Allogeneic Transplant Following Brentuximab Vedotin *1427*
49.4.1.4 Brentuximab Vedotin in Newly Diagnosed Hodgkin Lymphoma *1429*
49.4.2 Systemic Anaplastic Large Cell Lymphoma *1432*
49.4.2.1 Brentuximab Vedotin in Relapsed/Refractory Anaplastic Large Cell Lymphoma *1432*
49.4.2.2 Brentuximab Vedotin in Newly Diagnosed Anaplastic Large Cell Lymphoma *1433*
49.4.3 Primary Cutaneous CD30-Positive Lymphoproliferative Disorders *1433*
49.4.3.1 Brentuximab for the Treatment of Primary Cutaneous CD30-Positive Lymphoproliferative Disorders *1435*
49.4.4 Other CD30-Positive Hematologic Malignancies *1435*
49.5 Future Perspectives *1435*
Acknowledgments *1437*
References *1437*

50 Canakinumab (ILARIS®) *1445*
Hermann Gram
50.1 Introduction *1445*
50.2 Production, Pharmacology, and Pharmacokinetics of Canakinumab *1446*
50.2.1 Marketed Drug Product *1446*
50.3 Clinical Trials *1447*

50.3.1 Cryopyrin-Associated Periodic Syndrome (CAPS) *1448*
50.3.2 Gouty Arthritis *1450*
50.3.3 Systemic Juvenile Idiopathic Arthritis (sJIA) *1452*
50.3.4 Rheumatoid Arthritis *1454*
50.3.5 Type II Diabetes *1456*
50.3.6 Cardiovascular Risk *1457*
50.4 Outlook and Summary *1458*
References *1458*

51 Catumaxomab (Removab) – Trifunctional Antibodies: Combining Direct Tumor Cell Killing with Therapeutic Vaccination *1463*
Horst Lindhofer, Michael Stanglmaier, Raymund Buhmann, Michael Jäger, Daniel Klunker, Peter Ruf, and Juergen Hess
51.1 Introduction *1463*
51.1.1 Bispecific Antibodies Revisited *1464*
51.1.2 Focus on the trAb Immunogenicity in the World of Human(ized) bsAb Formats *1466*
51.2 Manufacturing of trAbs *1467*
51.3 The Mode of Action of trAbs in Tumor Treatment *1468*
51.3.1 The Role of the Fc Region *1470*
51.3.2 Vaccination-Like Effects Evoked by trAbs *1470*
51.3.3 TrAbs Can Be Combined with Chemotherapy and Eliminate Tumor Cells with Low Target Antigen Expression *1473*
51.4 From Bench to Bedside with the Triomab® trAb Family *1474*
51.4.1 Anti-EpCAM × Anti-CD3 Catumaxomab for Malignant Ascites Treatment *1474*
51.4.1.1 Systemic Treatment Outcome of Catumaxomab with Locoregional Administration *1478*
51.4.1.2 Catumaxomab-Based Treatment Regimes Against Peritoneal Carcinomatosis *1479*
51.4.1.3 With Catumaxomab toward Gastric Cancer Treatment *1480*
51.4.1.4 Intra- and Postoperative Application of Catumaxomab in Patients with Ovarian Cancer *1481*
51.4.2 Anti-HER2/neu × Anti-CD3 Ertumaxomab *1482*
51.4.3 Anti-CD20 × Anti-CD3 Lymphomun *1484*
51.4.4 Anti-GD2 × Anti-CD3 Ektomab *1488*
51.5 Potential Biomarkers Along trAb Treatment Concept *1490*
51.5.1 First Indicator for the Therapeutic Outcome: Development of Humoral ADA Responses *1490*
51.5.2 Initial Relative Lymphocyte Count as Pretherapeutic Indicator for Treatment Success *1491*
51.6 Concluding Remarks *1491*
Acknowledgments *1492*
References *1492*

52 **Cetuximab (Erbitux)** *1501*
Sonja Wilke and Michael Hust
52.1 Nature, Role in Disease, Biology of the Target *1501*
52.1.1 Biochemistry and Biology of Epidermal Growth Factor Receptor (EGFR) *1501*
52.1.2 Role in Cancer *1502*
52.2 Origin and Development of Erbitux *1503*
52.2.1 Monoclonal Antibody 225 *1503*
52.2.2 Chimerization *1503*
52.3 Mechanism of Action *1503*
52.3.1 Cetuximab Mechanism of Action *1503*
52.3.2 KRAS and Cetuximab *1505*
52.4 Preclinical and Clinical Results *1506*
52.4.1 Preclinical Results *1506*
52.4.2 Clinical Results for Colon Cancer *1506*
52.4.2.1 Monotherapy *1506*
52.4.2.2 Combination Therapy *1507*
52.4.3 Clinical Results for SCCHN *1509*
52.4.3.1 Monotherapy *1509*
52.4.3.2 Combination Therapy *1509*
52.4.4 Clinical Results for NSCLC *1510*
52.4.4.1 Monotherapy *1510*
52.4.4.2 Combination Therapy *1510*
52.4.5 Clinical Results of Other Tumors *1511*
52.5 Production *1511*
52.6 Cetuximab in Clinics *1511*
52.7 Outlook *1512*
References *1512*
Websites *1520*

53 **Denosumab (Prolia®)** *1521*
Torsten Meyer
53.1 Introduction *1521*
53.2 Clinical Studies *1522*
53.2.1 Phase 1 Study *1522*
53.2.2 Phase 2 Study *1523*
53.2.3 Phase 3 Studies *1524*
53.2.3.1 Phase 3 Study FREEDOM *1524*
53.2.3.2 Phase 3 Study STAND *1525*
53.2.3.3 Phase 3 Study HALT *1526*
53.3 Guidelines of the FDA (Website of FDA) for Denosumab (Prolia) *1526*
53.3.1 Guidelines of the FDA (Website of FDA) for Denosumab (Xgeva) *1527*
53.4 Summary and Outlook *1527*

References *1527*
Websites *1529*

54 Efalizumab (Raptiva) *1531*
Karlheinz Schmitt-Rau
54.1 Introduction *1531*
54.2 Development and Characterization of the Antibody *1531*
54.3 Efalizumab in the Treatment of Psoriasis *1533*
54.3.1 Psoriasis: Prevalence, Characteristics, and Therapeutic Options *1533*
54.3.2 Pathogenesis of Psoriasis *1533*
54.3.2.1 T-Cell Activation *1533*
54.3.2.2 T-Cell Migration and Extravasation *1534*
54.3.2.3 T-Cell Reactivation *1534*
54.3.3 Efalizumab: Mechanism of Action *1535*
54.4 Pharmacology and Toxicology of Efalizumab *1535*
54.4.1 Preclinical Studies *1535*
54.4.2 Pharmacodynamics *1536*
54.4.3 Pharmacokinetics *1537*
54.5 Clinical Development of Efalizumab *1538*
54.5.1 Randomized, Placebo-Controlled, Double-Blind Studies *1538*
54.5.2 Long-Term Efficacy *1538*
54.6 Health-Related Quality of Life (HRQoL) *1539*
54.7 Safety and Tolerability *1539*
54.8 Efalizumab: Reassessment of Benefit–Risk Ratio and Suspension of Marketing Authorization *1540*
References *1541*

55 Calicheamicin Conjugates: Gemtuzumab Ozogamicin (Mylotarg), Inotuzumab Ozogamicin *1545*
Matthias Peipp and Martin Gramatzki
55.1 Introduction *1545*
55.2 Target Antigen Selection in Therapy with ADC *1546*
55.2.1 CD33 in AML *1546*
55.2.2 CD22 Expression in B-Cell Neoplasias *1547*
55.3 Conjugate Design/Preclinical Activity *1548*
55.3.1 Gemtuzumab Ozogamicin *1548*
55.3.2 Inotuzumab Ozogamicin *1549*
55.3.3 The IgG4 Moiety *1549*
55.3.4 Calicheamicin *1549*
55.3.5 Design of Antibody–Calicheamicin Conjugates, Choice of Linker *1550*
55.4 Mechanisms of Action *1552*
55.5 Potential Mechanisms of Resistance *1552*
55.6 Clinical Trials *1553*
55.6.1 Gemtuzumab Ozogamicin (GO) *1553*

55.6.2 Inotuzumab Ozogamicin *1555*
55.7 Summary and Conclusions *1556*
References *1556*

56 Golimumab (Simponi®) *1565*
Sohini Mazumdar and Janice M. Reichert
56.1 Introduction *1565*
56.2 Characterization and Preclinical Evaluation *1568*
56.3 First-in-Humans Study *1568*
56.4 Pivotal Clinical Studies *1569*
56.4.1 Rheumatoid Arthritis *1569*
56.4.1.1 GO-FORWARD, GO-AFTER, and GO-BEFORE Studies in RA Patients *1570*
56.4.2 Psoriatic Arthritis *1571*
56.4.3 Ankylosing Spondylitis *1572*
56.4.4 Ulcerative Colitis *1573*
56.4.5 Ongoing Clinical Study in Juvenile Idiopathic Arthritis *1574*
56.5 Market Competitors *1575*
References *1575*

57 Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) *1579*
Karin Hohloch, Björn Chapuy, and Lorenz Trümper
57.1 Introduction *1579*
57.1.1 Epidemiology of Non-Hodgkin's Lymphoma *1579*
57.1.2 Standard Therapy of NHL *1580*
57.1.3 CD20-Targeted Immunotherapy of NHL *1580*
57.2 Basic Principles of Radioimmunotherapy *1581*
57.3 Development and Advantages of ^{90}Y-Ibritumomab Tiuxetan *1582*
57.3.1 Preparation of ^{90}Y-Ibritumomab Tiuxetan *1582*
57.3.2 Dosing of ^{90}Y-Ibritumomab Tiuxetan *1584*
57.4 Preclinical and Clinical Results *1585*
57.4.1 Preclinical Results *1585*
57.4.2 Clinical Therapeutic Efficacy *1585*
57.4.3 Adverse Events *1586*
57.4.4 Considerations for the Use of ^{90}Y-Ibritumomab Tiuxetan *1587*
57.5 Outlook *1588*
57.5.1 Novel Indications *1588*
57.5.1.1 Aggressive (DLBCL) NHL *1588*
57.5.1.2 RIT in Mantle Cell Lymphoma *1588*
57.5.2 Combination Therapy *1589*
57.5.3 ^{90}Y-Ibritumomab Tiuxetan Consolidation of Frontline Chemotherapy *1589*
57.5.4 ^{90}Y-Ibritumomab Tiuxetan as Conditioning Regimen for Stem Cell Transplantation *1590*
References *1592*

58 Infliximab (Remicade®) *1599*
Christian Antoni and Maria Wiekowski
58.1 Antibody Characteristics *1599*
58.2 Preclinical Characterization *1600*
58.3 Pharmacokinetics *1600*
58.4 Clinical Response *1601*
58.4.1 Therapeutic Indications *1601*
58.4.1.1 Crohn's Disease *1602*
58.4.1.2 Rheumatoid Arthritis *1603*
58.4.1.3 Ankylosing Spondylitis *1605*
58.4.1.4 Psoriatic Arthritis *1606*
58.4.1.5 Psoriasis *1607*
58.4.1.6 Ulcerative Colitis *1608*
58.4.1.7 Pediatric Ulcerative Colitis *1609*
58.5 Safety *1609*
58.5.1 Serious Infections *1609*
58.5.2 Antibody Formation against Infliximab *1611*
58.5.3 Infusion Reactions/Delayed Hypersensitivity Reactions *1611*
58.5.4 Autoantibody Formation *1612*
58.5.5 Neurological Disorders/Demyelinating Disease *1612*
58.5.6 Malignancies/Lymphoma *1612*
58.5.7 Congestive Heart Failure *1613*
58.5.8 Other Adverse Events (Hepatic Events and Pregnancy Outcome) *1613*
58.6 Summary *1614*
References *1614*

59 Ipilimumab (Yervoy®) *1619*
Teresa Alonso Gordoa, Javier Puente Vázquez, and Eduardo Díaz-Rubio
59.1 Introduction *1619*
59.2 Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) *1620*
59.3 Ipilimumab, Mechanism of Action *1621*
59.4 Pharmacokinetics *1622*
59.5 Melanoma *1622*
59.5.1 Initial Phase II Trials *1623*
59.5.2 Phase II Studies *1625*
59.5.3 Phase III Trials *1628*
59.5.4 Long Responders *1629*
59.5.5 Searching for Biomarkers *1630*
59.6 Prostate Cancer *1631*
59.7 Lung Cancer *1633*
59.8 Patterns of Response with Ipilimumab (Immune-Related Response Criteria) *1634*
59.9 Adverse Events *1636*

59.10 Conclusions *1641*
References *1641*

60 Muromonab-CD3 (Orthoclone OKT®3) *1645*
Harald Becker and Janice M. Reichert
60.1 Introduction *1645*
60.2 Production of mAbs *1646*
60.3 Pharmacology of Muromonab-CD3 *1647*
60.3.1 Pharmacokinetic Properties of Muromonab-CD3 *1648*
60.3.2 Pharmacodynamics of Muromonab-CD3 *1649*
60.3.3 Activation of Human T Cells *1650*
60.3.4 Immunogenicity *1650*
60.3.5 Interactions *1651*
60.4 Therapeutic Use *1652*
60.4.1 Renal and or Renal–Pancreas Transplant Recipients *1656*
60.4.2 Liver Transplant Recipients *1659*
60.4.3 Cardiac Transplant Recipients *1659*
60.5 Cytokine Release Syndrome *1659*
60.5.1 Pathophysiology of Cytokine Release Syndrome *1662*
60.5.2 Symptoms of Cytokine Release Syndrome *1663*
60.5.3 Muromonab-CD3 and Cytokine Release Syndrome *1665*
60.5.4 Management of Cytokine Release Syndrome *1666*
60.5.4.1 Methylprednisolone *1666*
60.5.4.2 Pentoxifylline *1668*
60.5.4.3 Indomethacin *1669*
60.5.4.4 Recombinant Human Soluble Tumor Necrosis Factor Receptor *1669*
60.5.4.5 Anti-TNF mAbs *1670*
60.6 Consequences of Immunosuppression *1670*
60.6.1 Infections *1670*
60.6.2 Neoplasia *1671*
60.7 Withdrawal from the Market *1672*
References *1672*

61 Nimotuzumab: A Humanized Anti-EGFR Antibody *1679*
Tania Crombet Ramos
61.1 Overview *1679*
61.2 Head and Neck *1679*
61.3 Glioma *1682*
61.4 Pediatric Glioma *1684*
61.5 Esophageal and Gastric Cancer *1684*
61.6 Pancreatic Cancer *1685*
61.7 Non-Small Cell Lung Cancer (NSCLC) *1686*
61.7.1 Patient Selection *1687*
61.7.2 Optimal Duration of Therapy *1688*
61.7.3 Pharmacodynamic Evaluation *1689*

61.7.4 Safety *1690*
61.8 Concluding Remarks *1690*
References *1690*

62 Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma *1695*
Christian Klein, Marina Bacac, Pablo Umaña, and Michael Wenger
62.1 *In vitro* Mechanism of Action of Type I and Type II CD20 Antibodies *1695*
62.2 Generation of Obinutuzumab *1697*
62.3 Obinutuzumab is a Classical Type II CD20 Antibody *1698*
62.4 The Epitope Recognized by Obinutuzumab *1699*
62.5 CDC Activity of Obinutuzumab *1701*
62.6 Direct Cell Death Induction by Obinutuzumab *1702*
62.7 Glycoengineering of Obinutuzumab *1704*
62.8 *In vitro* NK Cell and Neutrophil ADCC and Macrophage ADCP Activity of Obinutuzumab *1706*
62.9 *Ex vivo* Whole Blood B-Cell Depletion by Obinutuzumab *1708*
62.10 *In vivo* Activity of Obinutuzumab in Xenograft Models *1709*
62.11 *In vivo* Activity of Obinutuzumab in Combination with Chemotherapy, Bcl-2, and MDM2 Inhibitors *1712*
62.12 B-Cell Depletion by Obinutuzumab in Cynomolgus Monkeys *1713*
62.13 Conclusion from Nonclinical Pharmacology Studies with Obinutuzumab *1714*
62.14 Clinical Experiences with Obinutuzumab *1715*
62.15 Early Clinical Experience with Obinutuzumab in B-Cell Lymphoma *1715*
62.15.1 BO20999 Phase 1 *1715*
62.15.2 BO21003 Phase I *1715*
62.15.3 JO21900 *1717*
62.16 Phase Ib and II Experience with Obinutuzumab in B-Cell Lymphoma *1717*
62.16.1 BO20999 Randomized Phase II in Indolent B-Cell Lymphoma *1717*
62.16.2 BO21003 Randomized Phase II in Indolent Lymphoma *1718*
62.16.3 BO20999 Randomized Phase II in Aggressive B-Cell Lymphoma *1719*
62.16.4 BO21000 Randomized Phase II with Chemotherapy in Relapsed/Refractory Indolent B-Cell Lymphoma *1720*
62.16.5 BO21000 Randomized Phase II with Chemotherapy in Previously Untreated Indolent B-Cell Lymphoma *1720*
62.17 Phase III Studies with Obinutuzumab in B-Cell Lymphoma *1721*
62.18 Obinutuzumab in CLL: Early Experience and Ongoing Phase II Studies *1722*

62.19 Phase III Experience with Obinutuzumab: The CLL11 Trial *1722*
References *1723*

Volume IV: Approved Therapeutic Antibodies and in vivo Diagnostics

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

63 Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity *1733*
Margaret A. Lindorfer, Joost M. Bakker, Paul W.H.I. Parren, and Ronald P. Taylor

64 Omalizumab (Xolair) – Anti-Immunoglobulin E Treatment in Allergic Diseases *1775*
Claus Kroegel and Martin Foerster

65 Palivizumab (Synagis®) *1825*
Louis Bont

66 Panitumumab (Vectibix®): A Treatment for Metastatic Colorectal Cancer *1855*
Jonas Kügler

67 Pertuzumab (Perjeta®) *1871*
Jose Angel García-Saénz, Fernando Moreno Anton, and Coralia Bueno Muiño

68 Ranibizumab (Lucentis): a New Anti-Angiogenic Treatment in Ophthalmology *1883*
Nicolas Leveziel, Marc Ohresser, and Gilles Paintaud

69 Raxibacumab, Human Monoclonal Antibody against Anthrax Toxin *1899*
Sally D. Bolmer and Thi-Sau Migone

70 **Rituximab (Rituxan®)** *1909*
Axel Böhnke and Michael Wenger

71 **Tocilizumab (Actemra®)** *2023*
Graeme Jones and Changhai Ding

72 **Trastuzumab (Herceptin®) and Ado-Trastuzumab Emtansine (Kadcyla®): Treatments for HER2-Positive Breast Cancer** *2041*
Ruhe Chowdhury and Paul Ellis

73 **Ustekinumab (Stelara®)** *2069*
Oya Cingoz, Stefan Dübel, and Janice M. Reichert

74 **Abciximab (Reopro®), Bevacizumab (Avastin®), Certolizumab Pegol (Cimzia®), Eculizumab (Soliris®), Natalizumab (Tysabri®)** *2087*
Janice M. Reichert

75 **Itolizumab (Alzumab®), Mogamulizumab (Poteligeo®), and Tositumomab (Bexxar®)** *2063*
Stefan Dübel

Part VIII: In vivo Diagnostics *2121*

76 **Radiolabeled Antibodies for Diagnostic Imaging** *2123*
Christopher J. Palestro

Index *2143*

Contents

Volume I: Defining the Right Antibody Composition

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

1 **Therapeutic Antibodies – from Past to Future** *1*
Stefan Dübel and Janice M. Reichert

Part I: Selecting and Shaping the Antibody Molecule *15*

2 **Selection Strategies for Monoclonal Antibodies** *17*
Gerhard Moldenhauer

3 **Antibody Phage Display** *43*
Michael Hust, André Frenzel, Florian Tomszak, Jonas Kügler, and Stefan Dübel

4 **Transgenic Animals Derived by DNA Microinjection** *77*
Marianne Brüggemann, Michael J. Osborn, Biao Ma, Suzanne Avis, Ignacio Anegon, and Roland Buelow

5 **Humanization Strategies** *89*
José W. Saldanha

6 **Antibody Affinity** *115*
André Frenzel, Lorin Roskos, Scott Klakamp, Meina Liang, Rosalin Arends, and Larry Green

7 **Fc Engineering** *141*
Matthias Peipp, Stefanie Derer, Stefan Lohse, Christian Kellner, and Thomas Valerius

8 **Glycosylation of Antibody Molecules** *171*
Roy Jefferis

9 **Bioinformatics Tools for Analysis of Antibodies** *201*
Andrew C.R. Martin and James Allen

10 **How to Use IMGT® for Therapeutic Antibody Engineering** *229*
Marie-Paule Lefranc

Part II: Modified Antibodies *265*

11 **Bispecific Antibodies** *267*
Dafne Müller and Roland E. Kontermann

12 **Single-Domain Antibodies: An Overview** *311*
Carrie Enever, Edward Coulstock, Malgorzata Pupecka-Swider, and Bruce Hamilton

13 **Antibody–Drug Conjugates: New Frontier in Cancer Therapeutics** *341*
Rajeeva Singh, John M. Lambert, and Ravi V. J. Chari

14 **Antibody-Targeted Drugs: From Chemical Immunoconjugates to Recombinant Fusion Proteins** *363*
Athanasios Mavratzas, Michaela A.E. Arndt, Stefan Kiesgen, and Jürgen Krauss

Part III: Emerging Technologies *391*

15 **Emerging Technologies for Antibody Selection** *393*
Mingyue He and Michael J. Taussig

16 **Anti-Idiotypic Antibodies** *407*
Alejandro López-Requena, Oscar R. Burrone, and Rolando Pérez

17 **Non-Antibody Scaffolds as Alternative Therapeutic Agents** *435*
Markus Fiedler and Arne Skerra

18 **Antibody-Directed Enzyme Prodrug Therapy (ADEPT)** *475*
Surinder K. Sharma, Kerry A. Chester and Kenneth D. Bagshawe

19 **Engineered Antibody Domains as Candidate Therapeutics** *487*
Weizao Chen, Ponraj Prabakaran, and Dimiter S. Dimitrov

20 **Chimeric Antigen Receptors –"CARs"** *519*
Ulf Petrausch and Thomas Schirrmann

21 **Emerging Alternative Production Systems** *561*
Benjamin Sommer, Holger Laux, Andre Frenzel, and Thomas Jostock

Volume II: Clinical Development of Antibodies

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

Part IV: The Way into the Clinic *601*

22 **Process Development and Manufacturing of Therapeutic Antibodies** *603*
Alexander Jacobi, Barbara Enenkel, Patrick Garidel, Christian Eckermann, Mathias Knappenberger, Ingo Presser, and Hitto Kaufmann

23 **The Immunogenicity of Therapeutic Antibodies** *665*
Melody Sauerborn

24 **Biosimilar Monoclonal Antibodies** *681*
Susanne D. Pippig, Carsten Brockmeyer, and Robert E. Zoubek

25 **Patent Issues Relating to Therapeutic Antibodies** *705*
Barbara Rigby, Michael Braunagel, and Deborah Owen

Part V: Therapeutic Antibody Pipeline *735*

26 **Monoclonal Antibody Cancer Treatments in Phase III Clinical Trials** *737*
Ulf Petrausch and Peter Markus Deckert

27 **Antibodies in Cancer Treatment: Early Clinical Development** *787*
Matthew Zibelman, Hossein Borghaei, and Anthony J. Olszanski

28 **Targeting Angiogenesis by Therapeutic Antibodies** *823*
Onat Kadioglu, Ean Jeong Seo, and Thomas Efferth

29 **Antibodies in Phase III Studies for Immunological Disorders** *851*
Penelope Ward and Mark Bodmer

30 **Monoclonal Antibodies in Phase 1 and 2 Studies for Immunological Disorders** *927*
Frank R. Brennan

31 **MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders** *969*
Frank R. Brennan

32 **T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1079*
Frank R. Brennan

33 **B-Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1115*
Frank R. Brennan

34 **Inhibitors of Leukocyte Adhesion and Migration in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1127*
Frank R. Brennan

35 **Toll-Like Receptor Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1145*
Frank R. Brennan

36 **IgE Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1159*
Frank R. Brennan

37 **Complement Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1165*
Frank R. Brennan

38 **mAbs Targeting Apoptosis, Angiogenesis Inhibitors, and Other mAbs in Phase 1 and 2 Clinical Studies for Immunological Disorders** *1175*
Frank R. Brennan

39 ***In vitro* Studies and Clinical Trials about Monoclonal Antibodies Used in Infectiology** *1195*
Guillaume Desoubeaux

40 **Immunotherapeutics for Neurological Disorders** *1215*
Anne Messer, Kevin Manley, and Cynthia A. Lemere

Part VI: Gaining Marketing Approval *1231*

41 **Regulatory Considerations in the Development of Monoclonal Antibodies for Diagnosis and Therapy** *1233*
Marjorie A. Shapiro, Patrick G. Swann, and M. Stacey Ricci

42 **Regulatory Review: Clinical to Market Transition** *1263*
Gabriele Dallmann

43 **Monoclonal Antibody Nomenclature for Clinical Studies (USA)** *1283*
Stephanie C. Shubat

Volume III: Approved Therapeutic Antibodies

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

Part VII: Approved Therapeutic Antibodies *1289*

44 **Oligoclonal and Polyclonal Antibody Preparations** *1291*
Rishab K. Gupta and Mark C. Glassy

45 **Adalimumab (Humira®)** *1309*
Janice M. Reichert

46 **Alemtuzumab (Lemtrada, MabCampath)** *1323*
Thomas Elter, Michael Hallek, and Janice M. Reichert

47 **Basiliximab (Simulect®) and Daclizumab (Zenapax®)** *1375*
Nadim Mahmud, Burcin Taner, and Nasimul Ahsan

48 **Belimumab (Benlysta®)** *1405*
Pamela M. K Lutalo, Natasha Jordan, Thi-Sau Migone, and David P. D'Cruz

49 **Brentuximab Vedotin (Adcetris®) for the Treatment of CD30-Positive Hematologic Malignancies** *1417*
Niels W.C.J. van de Donk and Eugen Dhimolea

50 **Canakinumab (ILARIS®)** *1445*
Hermann Gram

51 **Catumaxomab (Removab) –Trifunctional Antibodies: Combining Direct Tumor Cell Killing with Therapeutic Vaccination** *1463*
Horst Lindhofer, Michael Stanglmaier, Raymund Buhmann, Michael Jäger, Daniel Klunker, Peter Ruf, and Juergen Hess

52 **Cetuximab (Erbitux)** *1501*
Sonja Wilke and Michael Hust

53 **Denosumab (Prolia®)** *1521*
Torsten Meyer

54 **Efalizumab (Raptiva)** *1531*
Karlheinz Schmitt-Rau

55 **Calicheamicin Conjugates: Gemtuzumab Ozogamicin (Mylotarg), Inotuzumab Ozogamicin** *1545*
Matthias Peipp and Martin Gramatzki

56 **Golimumab (Simponi®)** *1565*
Sohini Mazumdar and Janice M. Reichert

57 **Yttrium-90 Ibritumomab Tiuxetan (Zevalin®)** *1579*
Karin Hohloch, Björn Chapuy, and Lorenz Trümper

58 **Infliximab (Remicade®)** *1599*
Christian Antoni and Maria Wiekowski

59 **Ipilimumab (Yervoy®)** *1619*
Teresa Alonso Gordoa, Javier Puente Vázquez, and Eduardo Díaz-Rubio

60 **Muromonab-CD3 (Orthoclone OKT®3)** *1645*
Harald Becker and Janice M. Reichert

61 **Nimotuzumab: A Humanized Anti-EGFR Antibody** *1679*
Tania Crombet Ramos

62 **Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma** *1695*
Christian Klein, Marina Bacac, Pablo Umaña, and Michael Wenger

Volume IV: Approved Therapeutic Antibodies and in vivo Diagnostics

Quick Reference List of Antibodies by International Nonproprietary Name *XXIII*
Quick Reference List of Antibodies by Brand Name *XXV*
A Greeting by the Editors *XXVII*
Foreword to the First Edition *XXIX*
Foreword to the Second Edition *XXXI*
List of Contributors *XXXIII*
Abbreviations *LI*
Appendix: Marketed Monoclonal Antibodies Compendium *LXXXIII*

63 Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity *1733*
Margaret A. Lindorfer, Joost M. Bakker, Paul W.H.I. Parren, and Ronald P. Taylor
63.1 Introduction and Preliminary Comments *1733*
63.2 Physical and Immunochemical Characteristics of OFA Compared to RTX *1735*
63.2.1 Interactions with CD20 *1735*
63.2.2 Development and Characterization of OFA *1737*
63.2.3 Epitope Characterization *1737*
63.2.4 *In vitro* Investigations Demonstrate That OFA Is Far More Effective Than RTX in Promoting CDC of Cell Lines and of CLL Cells *1739*
63.3 Functional Characterizations *1743*
63.3.1 Dose Requirements for Sustained *In vivo* Activity of OFA in Preclinical Models *1743*
63.3.2 Clearance from the Circulation via the Mononuclear Phagocytic System (MPS) *1744*
63.3.3 On the Role of Neutrophils *1745*
63.3.4 C3b Deposition and Complement Receptors *1745*
63.3.5 Complement as a Confounding Factor *1745*
63.3.6 Mouse Models *1746*
63.3.7 No Apoptosis *1748*
63.4 CD20: It Is certainly a Good Target, but How Well Characterized Is It? *1748*
63.4.1 CD20 Is not Shed into the Bloodstream *1748*
63.4.2 CD20 on B Cells Can Be ''Shaved,'' Especially When Effector Functions Are Exhausted *1749*
63.4.3 After OFA or RTX Binding, CD20 Can Indeed Be Internalized, but Slowly *1752*
63.5 Key Results of Clinical Trials with OFA *1752*
63.5.1 Introduction *1752*
63.5.2 OFA Monotherapy for CLL: Phase 1/2 *1753*
63.5.3 OFA Monotherapy for FL: a Dose-Ranging Study *1753*

63.5.4 OFA Monotherapy: the Pivotal Trial for CLL *1756*
63.5.5 Combination with Chemotherapy: OFA plus FC for CLL *1757*
63.5.6 Combination with Chemotherapy: O-CHOP for FL *1758*
63.5.7 Combination with Chemotherapy: OFA plus Lenalidomide or Ibrutinib for CLL *1758*
63.5.8 OFA Monotherapy: RTX-Refractory FL *1759*
63.5.9 Rheumatoid Arthritis *1760*
63.6 Summary and Future Directions *1761*
Abbreviations *1762*
63.7 Disclosures *1762*
References *1763*

64 Omalizumab (Xolair) – Anti-Immunoglobulin E Treatment in Allergic Diseases *1775*
Claus Kroegel and Martin Foerster
64.1 Introduction *1775*
64.2 The Biology of the IgE Molecule *1778*
64.2.1 IgE Distribution and Blood Concentration *1779*
64.2.2 IgE Synthesis and Regulation *1779*
64.3 IgE Receptors *1780*
64.3.1 FcεRI (High-Affinity IgE Receptor) *1781*
64.3.1.1 FcεRI–IgE Binding *1781*
64.3.1.2 FcεRI Activation *1782*
64.3.1.3 Regulation of FcεRI Expression *1783*
64.3.2 FcεRII (Low-Affinity IgE Receptor, CD23) *1783*
64.3.2.1 FcεRII–IgE Binding *1784*
64.3.2.2 FcεRII Activation *1784*
64.3.2.3 FcεRII/CD23 Functions *1784*
64.4 Cell Distribution of IgE *1785*
64.4.1 Effector Cell-Associated IgE *1785*
64.4.2 Antigen-Presenting Cell-Associated IgE *1786*
64.5 Physiologic and Pathophysiologic Significance of IgE *1786*
64.6 The Concept of Anti-IgE-Based Treatment *1787*
64.7 Construction of the Monoclonal Anti-IgE Molecule *1787*
64.7.1 Antibody Generation *1787*
64.7.2 Complex Formation and Tissue Distribution *1788*
64.7.3 Interactions with IgE *1792*
64.8 Efficacy *1792*
64.8.1 Preclinical Results *1792*
64.8.2 Clinical Studies *1793*
64.9 Anti-Inflammatory Effects of Omalizumab *1797*
64.9.1 Effects on Serum Free IgE Levels *1797*
64.9.2 Effect on Cytokines *1799*
64.9.3 Effects on FcεRI Cell Expression *1799*
64.9.4 Effect on Dendritic Cell APCs *1800*

64.9.5 Effect on Eosinophils *1800*
64.9.6 Effects on B Cells *1801*
64.10 Pharmacological Properties of Omalizumab *1802*
64.10.1 Pharmacodynamics *1802*
64.10.2 Pharmacokinetics *1802*
64.11 Adverse Effects *1802*
64.11.1 Systemic Side Effects *1803*
64.11.2 Local Reactions *1803*
64.11.3 Serious Adverse Effects *1803*
64.11.4 Immune Complex Diseases *1804*
64.11.5 Long-Term Adverse Effects *1804*
64.12 Indications *1804*
64.13 Contraindications *1804*
64.14 Preparation for Use *1805*
64.15 Administration *1806*
64.16 Dosing of Omalizumab *1806*
64.17 Response to Treatment *1808*
64.17.1 Onset of Action of Anti-Immunoglobulin E Effect *1808*
64.17.2 Duration of Treatment *1808*
64.18 Assessment of Therapeutic Response *1809*
64.19 Monitoring of Therapy *1810*
64.20 Drug Interactions *1810*
64.21 Pregnancy and Lactation *1810*
64.22 Cost *1811*
64.23 Non-approved Diseases *1811*
64.23.1 Allergic Rhinitis *1811*
64.23.2 Urticaria/Angioedema *1812*
64.23.3 Insect Venom Allergy and Specific Immunotherapy *1813*
64.23.4 Mast Cell Activation Syndrome (MCAS) *1814*
64.24 Conclusions *1814*
Acknowledgments *1815*
References *1815*
Websites *1824*

65 Palivizumab (Synagis®) *1825*
Louis Bont
65.1 Nature, Role in Disease, and Biology of the Target *1825*
65.1.1 Respiratory Syncytial Virus (RSV)-Induced Disease and RSV Epidemiology *1825*
65.1.2 Target of the Antibody: the RSV Virion *1826*
65.1.3 Correlates of Protection from Disease *1827*
65.2 Origin, Engineering, and Humanization of the Antibody *1829*
65.3 Mechanism of Action and Preclinical Results *1831*
65.4 Production, Downstream Processing, and Galenics of the Antibody *1833*

65.5 Summary of Results from Clinical Studies *1835*
65.5.1 Phase 3 Trials *1835*
65.5.1.1 Palivizumab in Premature Infants *1836*
65.5.1.2 Palivizumab in Children with Significant Congenital Heart Disease (CHD) *1838*
65.6 Indications and Usage *1839*
65.7 Clinical Reports after Approval *1840*
65.8 Protective Efficacy as a Function of Palivizumab Serum Concentration? *1842*
65.9 Postmarketing Experience with Regard to Adverse Events (AEs) *1843*
65.10 Toward Improved Versions of Palivizumab *1845*
65.11 Summary *1845*
Acknowledgments *1846*
Abbreviations *1846*
References *1847*

66 Panitumumab (Vectibix®): A Treatment for Metastatic Colorectal Cancer *1855*
Jonas Kügler
66.1 Introduction *1855*
66.1.1 Colorectal Cancer *1855*
66.1.2 Epidermal Growth Factor *1855*
66.2 Panitumumab (Vectibix) *1856*
66.2.1 Panitumumab (Vectibix) Development *1856*
66.2.2 Preclinical Results of Panitumumab (Vectibix) *1857*
66.2.3 Resistance to Panitumumab (Vectibix) *1857*
66.2.4 Approval *1858*
66.2.5 Production, Galenics, and Pharmacokinetic Properties of Panitumumab *1858*
66.3 Results from Clinical Studies *1859*
66.3.1 Phase I Clinical Studies: Safety, Pharmacokinetics, and Activity *1859*
66.3.2 Monotherapy of Panitumumab for mCRC *1859*
66.3.3 First-Line Combination Therapy of Panitumumab for mCRC *1862*
66.3.4 Second-Line Combination Therapy of Panitumumab for mCRC *1862*
66.3.5 Antibody Combination Therapy *1863*
66.3.6 Panitumumab in Head and Neck Cancer *1864*
66.4 Summary and Outlook *1865*
References *1865*

67 Pertuzumab (Perjeta®) *1871*
Jose Angel García-Saénz, Fernando Moreno Anton, and Coralia Bueno Muiño
67.1 HER2-Positive Breast Cancer *1871*
67.2 Mechanisms of Trastuzumab Resistance *1871*
67.2.1 Loss of Trastuzumab Binding *1871*

67.2.2 Activation of Downstream Signaling Pathways *1872*
67.2.3 Overexpression of Alternative ErbB Ligands and Dimerization of Receptors *1873*
67.2.4 Interaction of HER2 with Other Structurally Unrelated Receptors *1873*
67.3 Preclinical Development *1874*
67.4 Pertuzumab Clinical Development *1875*
67.5 Pertuzumab Cardiac Safety Profile *1879*
References *1880*

68 Ranibizumab (Lucentis): a New Anti-Angiogenic Treatment in Ophthalmology *1883*
Nicolas Leveziel, Marc Ohresser, and Gilles Paintaud
68.1 Introduction *1883*
68.1.1 Age-Related Macular Degeneration *1884*
68.1.2 Diabetic Macular Edema *1886*
68.1.3 Branch and Central Retinal Vein Occlusion *1886*
68.1.4 Myopic Choroidal Neovascularization *1886*
68.2 Ranibizumab: Clinical Studies in Retinal Disorders *1887*
68.2.1 Exudative AMD *1887*
68.2.2 Clinical Studies in Diabetic Macular Edema *1889*
68.2.3 Clinical Studies in Retinal Vein Occlusion *1890*
68.2.4 Clinical Studies in Myopic Choroidal Neovascularization *1891*
68.3 Other Molecules with Anti-VEGF Effect of Clinical Use in Retinal Disorders *1891*
68.3.1 Bevacizumab *1892*
68.3.2 Aflibercept *1893*
References *1894*

69 Raxibacumab, Human Monoclonal Antibody against Anthrax Toxin *1899*
Sally D. Bolmer and Thi-Sau Migone
69.1 Introduction *1899*
69.2 Development of Raxibacumab *1900*
69.2.1 Anthrax Toxins *1900*
69.2.2 Molecule Generation and *In vitro* Pharmacology *1901*
69.2.2.1 Generation of Raxibacumab *1901*
69.2.2.2 Raxibacumab Mechanism of Action *1901*
69.3 Demonstration of Effectiveness under the Animal Rule *1901*
69.3.1 Animal Models *1902*
69.3.2 Monotherapy Studies *1903*
69.3.3 Antibiotic Combination Studies *1904*
69.4 Safety *1905*
69.4.1 Nonclinical Safety *1905*
69.4.2 Human Safety *1905*

69.5 Dosing *1906*
69.6 Indication *1906*
69.7 Conclusion *1907*
Abbreviations *1907*
References *1907*

70 Rituximab (Rituxan®) *1909*
Axel Böhnke and Michael Wenger
70.1 Introduction *1909*
70.1.1 Production, Design, and Structure of Rituximab *1909*
70.1.2 CD20 as a Therapeutic Target *1910*
70.1.3 Mode of Action *1911*
70.1.4 Preclinical Studies *1913*
70.1.5 Pharmacokinetic Studies *1913*
70.2 Rituximab Clinical Data in B-Cell Lymphoma *1914*
70.2.1 Overview of B-Cell Lymphoma *1914*
70.2.1.1 Overview of Indolent and Aggressive B-Cell Lymphoma *1914*
70.2.1.2 Overview of CLL *1916*
70.2.2 Rituximab plus Chemotherapy Induction Therapy in Indolent B-Cell Lymphoma *1917*
70.2.2.1 Rituximab plus Chemotherapy in Previously Untreated Indolent B-Cell Lymphoma *1922*
70.2.2.2 Rituximab plus Chemotherapy in Relapsed/Refractory Indolent B-Cell Lymphoma *1927*
70.2.2.3 Meta-Analysis of Rituximab and Chemotherapy in Indolent B-Cell Lymphoma *1930*
70.2.3 Induction Therapy with Rituximab plus Immune Modulators in Indolent B-Cell Lymphoma *1931*
70.2.3.1 Rituximab Plus Immune System Modulators in Previously Untreated Indolent B-Cell Lymphoma *1931*
70.2.3.2 Rituximab plus Immune Modulators in Relapsed/Refractory Indolent B-Cell Lymphoma *1932*
70.2.4 Induction with Rituximab Monotherapy in Indolent B-Cell Lymphoma *1933*
70.2.4.1 Rituximab Monotherapy in Previously Untreated Indolent B-Cell Lymphoma *1933*
70.2.4.2 Rituximab Monotherapy in Relapsed Indolent B-Cell Lymphoma *1934*
70.2.5 Rituximab in Other Subtypes of Indolent Lymphoma *1935*
70.2.5.1 Rituximab in Marginal Zone Lymphoma *1935*
70.2.5.2 Rituximab in Small Lymphocytic Lymphoma *1936*
70.2.5.3 Rituximab in Waldenström's Macroglobulinemia *1936*
70.2.6 Rituximab Maintenance Therapy in Indolent Lymphoma *1937*
70.2.6.1 Rituximab Maintenance Therapy Following Monotherapy Induction *1937*